Skip to main content
PLOS One logoLink to PLOS One
. 2026 Nov 18;21(11):e0363225. doi: 10.1371/journal.pone.0363225

Analysis of the biological characteristics and gene function of Lactobacillus delbrueckii subsp. sunkii

Yi Wu 1,*,#, Chunlei Zhang 1,#, Mengjie Luo 1, Feng Hai 2, Xianhua Liu 1, Xian Jin 1
Editor: António Machado3
PMCID: PMC13781413  PMID: 43050492

Abstract

The biological characteristics, morphology, and genomic information of Lactobacillus delbrueckii subsp. sunkii, isolated from the vaginal secretions of pregnant women, have not yet been reported. Elucidating its biological properties and genetic functions may provide a theoretical foundation for developing probiotic preparations to treat bacterial vaginosis. The strain was identified as L. delbrueckii subsp. sunkii using mass spectrometry and 16S ribosomal RNA (16S rRNA) gene sequencing. Colony morphology was observed, Gram staining characteristics were examined, and cellular ultrastructure was visualized via scanning electron microscopy (SEM). Whole-genome sequencing was performed using both second- and third-generation sequencing platforms, followed by comprehensive bioinformatics analysis. Additionally, biochemical experiments, H2O2 production tests, acid production assays, antibacterial activity assays, and antimicrobial susceptibility tests were conducted. The strain is a Gram-positive, rod-shaped, facultative anaerobe that possesses sparse filamentous, white, spine-like pili on its surface. It efficiently ferments sugars to produce acid but does not produce H2O2. While susceptible to 7 common antibiotics, it is resistant to sulfonamides. It inhibits the growth of Escherichia coli, Staphylococcus aureus, and Streptococcus agalactiae, and produces α-hemolytic rings on blood agar. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Clusters of Orthologous Groups (COG) annotations indicated that the strain is primarily involved in metabolic pathways. The Comprehensive Antibiotic Resistance Database (CARD) annotated 10 antibiotic resistance genes, including those for macrolides, tetracyclines, peptides, lincosamides, glycopeptides, penams, fluoroquinolones, streptogramins, nitroimidazoles, and pleuromutilins. L. delbrueckii subsp. sunkii exhibits strain-dependent variations in morphology, biochemical reactions, and nucleotide sequences. H2O2 production is not a universal feature among strains of this subspecies. It exhibits strong acid production from sugars and high susceptibility to most antibiotics, but shows a genotype-phenotype discrepancy in resistance, as sulfonamides do not inhibit its growth. These findings suggest that this subspecies may be associated with human metabolism and vaginal microbiota balance. However, further animal studies are needed to confirm its functional significance in the human vaginal environment.

Introduction

Lactic acid bacteria colonize the human gastrointestinal and urogenital tracts and are integral to human microbial communities [1]. L. delbrueckii, a key species within the genus Lactobacillus, comprises six subspecies: L. delbrueckii subsp. delbrueckii, L. delbrueckii subsp. lactis, L. delbrueckii subsp. bulgaricus, L. delbrueckii subsp. indicus, L. delbrueckii subsp. sunkii, and L. delbrueckii subsp. jakobsenii [2–4]. Studies have shown that the six subspecies of L. delbrueckii differ in their repertoires of subspecies-specific gene gains and losses [5]. Horizontal gene transfer analyses indicated that frequent gene transfers occurred between different subspecies when they first diverged from the common ancestor, but recent gene exchanges have remained confined to individual subspecies, implying that the six subspecies have undergone independent evolutionary processes since then. The subspecies lactis, jakobsenii, delbrueckii, and sunkii were more closely related to each other than to the bulgaricus and indicus subspecies. These four subspecies all show increasing genetic variability with increasing genome size; they can be distinguished by their specific gene contents. Carbohydrate metabolism in L. delbrueckii subsp. bulgaricus is primarily focused on lactose fermentation and a small range of additional carbohydrates. In contrast, L. delbrueckii subsp. lactis is capable of fermenting a variety of plant-derived sugars, such as maltose, mannose, sucrose, and trehalose. Meanwhile, L. delbrueckii subsp. sunkii and L. delbrueckii subsp. jakobsenii are negative for lactose fermentation. Numerous studies have focused on L. delbrueckii, yet most have concentrated on L. delbrueckii subsp. bulgaricus [6] and L. delbrueckii subsp. lactis [7], while research on L. delbrueckii subsp. sunkii remains scarce. Current investigations into this species have predominantly targeted applications in the food industry [8,9] and animal husbandry [10,11], with minimal exploration into disease prevention, therapy, or clinical healthcare. Based on phylogenetic trees constructed from amplified fragment length polymorphism (AFLP) profiles and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS) patterns, Kudo et al. [3] identified L. delbrueckii subsp. sunkii as a novel subspecies. However, their study was limited to morphological, physiological, and biochemical characterizations of the strains, and did not include detailed analyses of their whole-genome sequences, gene function annotations, or ultrastructural morphology. In accordance with Rule 54 of the International Code of Nomenclature of Prokaryotes, Goo et al. [12] proposed L. delbrueckii subsp. allosunkii nom. nov. as a replacement name for L. delbrueckii subsp. sunkii in 2024, which was originally reported by Kudo et al. [3] in 2012. The literature databases contain limited information on L. delbrueckii subsp. sunkii, particularly regarding strains derived from vaginal secretions of pregnant women—a finding not previously reported. Indeed, there are few reports on the unique value and significance of L. delbrueckii subsp. sunkii in the vaginal microbiota. To investigate the role of this bacterium in disease prevention and treatment, we isolated and cultured it in a preliminary study and examined its biological characteristics, including morphological and structural features, culture characteristics, and biochemical reactions. Additionally, we completed whole-genome nucleotide sequencing and annotated its gene functions, including resistance genes and signaling pathways. These efforts help fill a gap in this field. Moreover, by examining the morphological, biological, and genomic properties described above, along with in vitro acid production tests, antibacterial activity tests, and antimicrobial susceptibility tests, our study provides a foundation for the subsequent construction of antibacterial animal models and further exploration of resistance mechanisms.

Materials and methods

Study subjects

This project was approved by the Ethics Committee of Shenzhen Yantian District People’s Hospital and the Health Bureau of Yantian District, Shenzhen (No. YTWS 20230203). The study was conducted with the informed consent of the patients and in accordance with the principles of the Declaration of Helsinki. From September 1 to November 30, 2020, a total of 15 third-trimester pregnant women were recruited from the obstetric outpatient clinic of Yantian District People’s Hospital in Shenzhen. The third trimester of pregnancy is defined as the period from 28 weeks of gestation until delivery. The included participants were aged 25–35 years, with a gestational age of 35 ± 4 weeks. Exclusion criteria included clinical gynecological inflammation, abnormal vaginal microbiome, fetal developmental abnormalities, or recent antibiotic use. All participants provided written informed consent.

Sample collection and isolation

A sterile cotton swab (Jiangsu Kangjian, China) was used to gently rotate and collect secretions from the posterior vaginal fornix of pregnant women, and the swab was immediately streaked onto MRS blood agar plates in designated sectors. The plates were then incubated in an MCO-18 AC incubator (Panasonic, Japan) at 35 °C with 5% CO2 for 48 hours. Subsequently, suspected colonies were selected and subcultured on modified acidified blood agar plates containing 5% NaCl for further purification.

Observation of colony growth, bacterial morphology, and preliminary species identification

After 48 hours of incubation, colony growth was observed and Gram staining was performed. Additionally, a GeminiSEM 300 scanning electron microscope (ZEISS, Germany) was used to examine the bacterial ultrastructure. For SEM analysis, samples were coated with platinum using an ion sputter coater, placed in the microscope chamber, and examined at an acceleration voltage of 5 kV and a working distance of 4.8 mm after evacuation. Focusing, astigmatism correction, and contrast/brightness adjustments were performed prior to image acquisition. Pure colonies were selected for preliminary identification. According to the manufacturer’s instructions, a Microflex LT/SH mass spectrometer (Bruker Daltonics, Germany) was used following the steps below: (1) Sample preparation: Prepare the sample solution using formic acid and acetonitrile extraction. (2) Using a micropipette, spot 1 µL of the sample solution onto the target plate and allow it to air dry; then add 1 µL of alpha-cyano-4-hydroxycinnamic acid (CHCA) matrix solution dropwise and allow it to air-dry again before loading the plate into the instrument. (3) Calibrate the instrument. (4) Enter sample information. (5) Collect spectra, perform identification, and generate the report. (6) Clean the target plate.

H2O2 test, biochemical reaction tests, acid production test, antibacterial activity test, and antibiotic susceptibility test

For the H2O2 test, 50 µL of 3% H2O2 solution was placed on a clean glass slide. A colony of L. delbrueckii subsp. sunkii was picked using a sterile inoculation needle and mixed with the solution, and bubble formation was observed. For biochemical reaction tests, a bacterial suspension of L. delbrueckii subsp. sunkii adjusted to a 0.5 McFarland standard was prepared and inoculated into Gram-negative (GN) and Gram-positive (GP) identification cards (bioMérieux, France). For the acid production test, 1 mL of 5% glucose solution and 0.1 mL of 0.5 McFarland bacterial suspension were added to each of 10 tubes containing 5 mL of nutrient broth medium (Bohu Company, China). The antibacterial activity test was repeated three times using the spot-on-lawn method. The 0.5 McFarland bacterial suspension was spread on one side of a 9 cm blood agar plate. A standard strain of E. coli (ATCC 25922), S. aureus (ATCC 25923), or S. agalactiae (ATCC 13813) was picked with an inoculation needle and streaked onto the center of the streaked area. The same standard strain was also inoculated on the opposite side of the plate as a control. For the antibiotic susceptibility test, the 0.5 McFarland suspension of L. delbrueckii subsp. sunkii was swabbed onto blood agar plates following the Kirby-Bauer (K-B) method. A total of 20 antibiotic discs (Wenzhou Kangtai Biotechnology Co., Ltd., China) were tested in parallel, with five antibiotic discs placed on each plate. E. coli (ATCC 25922) and S. aureus (ATCC 25923) were used as quality control strains. Testing was performed strictly according to the instructions of the reagent kit manufactured by Zhuhai Dier Bioengineering Co., Ltd. (China). To each well of the DL-96STREP reagent plates, 100 µL of M-H broth containing 0.5 McFarland standard bacterial suspension was added. The plates were incubated at 35 °C for 24 hours, and the results were then read. Partial antimicrobial susceptibility testing was performed in strict accordance with the Clinical and Laboratory Standards Institute (CLSI) M45 (3rd Edition): Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. After 48 hours of incubation, the isolates were identified using GN and GP biochemical identification cards, and the biochemical reaction results were interpreted using a VITEK 2 Compact system (bioMérieux, France). Glucose concentration and pH in the nutrient broth were measured by the hexokinase method and potentiometry, using an AU5800 analyzer (Beckman, USA) and an ABL90 blood gas analyzer (Radiometer, Denmark), respectively. For these measurements, 1 mL of nutrient broth was centrifuged at 3,000 × g for 5 minutes, and 500 µL of the supernatant was then used for glucose and pH detection. The diameters of the inhibition zones were measured using a 0–150 mm digital caliper (Aerospace Ruibo, China) to determine susceptibility.

DNA extraction and sequencing

The colonies were scraped from the culture medium using sterile cotton swabs. Bacterial genomic deoxyribonucleic acid (DNA) was extracted in a biosafety cabinet, following the manufacturer’s instructions for the D3146 HiPure Bacterial DNA Kit (Magen, China). The specific operational steps were as follows: 1) Add the harvested bacterial cells to a mixture of 100 µL of Buffer STE Plus, 30 µL of Lysozyme, and 10 µL of RNase A, mix by inversion, and incubate at room temperature for 20 minutes. Then, add 200 mg of glass beads to the mixture and vortex at high speed for 15 minutes to lyse the bacteria. 2) After lysis, let the sample stand for 3 minutes, then transfer 250 µL of the supernatant to a new sterile centrifuge tube. Add 250 µL of Buffer DL and 10 µL of Proteinase K, mix by inversion, and digest at 70 °C for 10 minutes. 3) Add 250 µL of anhydrous ethanol to the tube, vortex for 30 seconds, then transfer the mixture to the HiPure DNA Mini Column and centrifuge at 10,000 × g for 2 minutes; discard the flow-through. 4) Add 500 µL of Buffer GW1 to the HiPure DNA Mini Column and centrifuge at 10,000 × g for 1 minute, discard the flow-through, then add 650 µL of Buffer GW2 for the second wash, centrifuge at 10,000 × g for 1 minute, and discard the flow-through. 5) Transfer the HiPure DNA Mini Column to a new 1.5-mL centrifuge tube, add 50 µL of Buffer AE (preheated to 70 °C) to the center of the column membrane, incubate for 3 minutes, and centrifuge at 10,000 × g for 1 minute to elute the DNA. The extracted bacterial genomic DNA was quantified using a microplate reader, and its integrity was verified by agarose gel electrophoresis. The qualified DNA was stored at −20 °C for future use.

16S rRNA gene amplification

In a 0.5 mL polymerase chain reaction (PCR) tube, 15 μL of Super Mix enzyme mixture was mixed with 1 μL each of the forward (27F) and reverse (1492R) primers (S1 Table), 1 μL DNA template, and 12 μL nuclease-free double-distilled water (ddH2O) to bring the final volume to 30 μL. The mixture was briefly pulsed at high speed for 5 s and subjected to PCR amplification under the following conditions: 96 °C for 5 min (initial denaturation); followed by 35 cycles of 96 °C for 20 s (denaturation), 62 °C for 20 s (annealing), 72 °C for 30 s (extension); followed by a final extension at 72 °C for 10 min; the amplification products were then held at 16 °C.

Detection, purification, and sequencing of 16S rRNA amplicons

The PCR products (3 μL) were electrophoresed on a 1.0% agarose gel to confirm the presence and intensity of bands of the expected size of approximately 1,500 base pairs (bp). Bands of the expected size were observed, and purification was performed using a magnetic bead-based purification kit (Shuomei Co., Ltd., China) according to the manufacturer’s protocol. The purified products were then subjected to Sanger sequencing.

Library preparation and quality control for HiSeq and PacBio platforms

Genomic DNA (100 ng) was sheared into fragments (<500 bp) using a Covaris S220 ultrasonicator. The fragments were subsequently end-repaired and ligated with sequencing adapters using the End Prep Enzyme Mix, and then purified with magnetic beads. Subsequently, amplification was performed using P5 and P7 primers (S1 Table). Library quality was examined using an Agilent 2100 Bioanalyzer (Agilent Technologies, USA), and library concentration was quantified using a Qubit 3.0 Fluorometer. Qualified libraries were used for cluster generation, and second-generation sequencing was conducted on the Illumina NovaSeq 6000 sequencer (Illumina, USA). For PacBio Sequel II third-generation sequencing (PacBio, USA), 5–10 µg of high-quality genomic DNA was sheared into fragments of approximately 10 kb using a Covaris g-TUBE. The SMRTbell library was constructed using the DNA Template Prep Kit. The validated SMRTbell library, combined with sequencing primers and polymerase, was loaded onto the PacBio Sequel platform by diffusion-based loading for sequencing according to data volume requirements.

Sequencing data processing and bioinformatics analysis

The Sanger sequencing results were analyzed and species identification was performed using the Basic Local Alignment Search Tool (BLAST) program available on the National Center for Biotechnology Information (NCBI) website. Additionally, MEGA (version 7.0) software was used to construct a phylogenetic tree based on the obtained 16S rRNA gene sequence of L. delbrueckii subsp. sunkii WuYi 2021−1 and the 12 most similar species sequences in the database. In a separate step, the raw image data from the HiSeq and PacBio sequencing platforms were processed using Bcl2fastq (version 2.20) for base calling. The raw sequencing data (Pass Filter Data) were further processed with the quality control software Cutadapt (version 1.9.1) to remove adapters and low-quality sequences, yielding high-quality clean data for downstream analysis. The de novo genome analysis workflow comprised the following five steps:

  • (1)

    Data Quality Control: Adapter sequences and low-quality reads were removed from second-generation sequencing data, and reads shorter than 500 bp were filtered out from Single Molecule Real-Time (SMRT) third-generation sequencing data to obtain the final clean data. PCR-negative controls (water blanks) were included, with Q30 scores of ≥80%.

  • (2)

    Genome Assembly and Correction: Firstly, we obtained preliminary assembly results from third-generation sequencing data using software such as HGAP4 [13], Falcon (version 0.3) [14], and Canu (version 0.7) [15]. We then compared the third-generation sequencing data with the assembly results and corrected them using Arrow. Afterwards, we compared the quality-filtered second-generation sequencing data to the assembly results and further corrected them using Pilon to obtain the final assembly results [16].

  • (3)

    Genome Component Analysis: Functional genes were predicted using Prodigal (version 3.02) [17]. Non-coding ribonucleic acids (RNAs), including tRNAs and rRNAs, and repeats were annotated using tRNAscan, barrnap, and alignment against the Rfam (version 12.0) database.

  • (4)

    Gene Function Annotation: The predicted coding genes were compared against protein sequences in various databases, including the Non-Redundant Protein Sequence Database (NR), KEGG, Gene Ontology (GO), COG, Carbohydrate-Active enZymes Database (CAZy), Protein families database (Pfam), Swiss-Prot, and CARD, using BLAST (version 2.2.31+) [18], to obtain gene function annotations.

  • (5)

    Additional Analyses: Secretory proteins, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) arrays, and prophages were predicted. The genome circular map was generated using Circos (version 0.69) [19].

Benchmarking Universal Single-Copy Orthologs (BUSCO) version 5.4.7 was installed via Conda (conda install -c bioconda busco = 5.4.7). A bacterial lineage database was selected based on the QUality ASsessment Tool (QUAST) evaluation of the L. delbrueckii genome assembly, which met the N50 threshold. Open reading frames were predicted from the input FASTA genome, and HMMER was used with the lineage-specific HMM to identify conserved single-copy orthologs. Genes with an alignment score that was ≥ 90% of the HMM self-score and a length within 2 standard deviations of the family mean were classified as complete.

Virulence factor annotation using the virulence factor database

Homology searches were performed using DIAMOND v2.2.5 in BLASTP mode with the --very-sensitive parameter and an E-value cutoff of 1 × 10-5. The predicted protein sequences of the L. delbrueckii subsp. sunkii strain were queried against the Virulence Factor Database (VFDB) Set A (core) and Set B (complete) protein datasets (VFDB: https://www.mgc.ac.cn/VFs) [20,21].

Results

Colony morphology and staining characteristics

L. delbrueckii subsp. sunkii formed moist, glistening colonies on modified blood agar plates, with smooth margins, slightly raised edges, and a depressed center, and exhibited α-hemolysis (S1 Fig). Under light microscopy, the subspecies displayed a Gram-positive, long rod-shaped morphology (Fig 1). SEM revealed bacterial cells of varying lengths and sizes, approximately 1–10 μm long (Fig 2). Additionally, the bacterial cell surface was covered with sparse filamentous fimbriae and sparse, white, spine-like fimbriae (Fig 3). Most cells showed concave pores at one pole (Fig 4). The bacteria were non-flagellated and non-spore-forming.

Fig 1. Gram-positive staining of Lactobacillus delbrueckii subsp. sunkii (digitally scanned at 40 × magnification).

Fig 1

Fig 2. Morphological structure of Lactobacillus delbrueckii subsp. sunkii under scanning electron microscopy (SEM).

Fig 2

Fig 3. SEM micrograph of Lactobacillus delbrueckii subsp. sunkii surface features.

Fig 3

Fig 4. SEM image showing concave pores on Lactobacillus delbrueckii subsp. sunkii cells.

Fig 4

H2O2 test and biochemical reaction results of GP and GN identification cards

The L. delbrueckii subsp. sunkii tested negative in the H2O2 test. The GP bacterial identification card yielded positive results for all of the following: arginine dihydrolase 1 (ADH1), α-glucosidase (AGLU), alanine-phenylalanine-proline arylamidase (APPA), α-galactosidase (AGAL), alanine arylamidase (AlaA), D-maltose (dMAL), D-mannitol (dMAN), D-mannose (dMNE), salicin (SAL), sucrose (SAC), arginine dihydrolase 2 (ADH2s), and optochin tolerance (OPTO). For the GN bacterial identification card, positive reactions were noted for APPA, D-glucose (dGLU), dMAN, dMNE, D-sorbitol (dSOR), and SAC, whereas negative reactions were noted for D-cellobiose (dCEL), L-proline arylamidase (ProA), and coumarate (CMT).

Acid production, antibacterial activity, and antibiotic susceptibility results

After 48 hours, the glucose concentration in each of the 10 tubes containing 5 mL of nutrient broth medium decreased from 277 ± 5 mmol/L to 138 ± 5 mmol/L. The pH of the medium dropped from 7.8 ± 0.2 to 4.0 ± 0.2. After 48 hours of incubation on blood agar plates, visible inhibition of E. coli (S2 Fig) and S. aureus (S3 Fig) was observed, along with inhibition of S. agalactiae growth. The mean antibiotic susceptibility results for L. delbrueckii subsp. sunkii from three tests were compared with those of control strains. After confirmation by both broth microdilution and disk diffusion, only the sulfonamide agents showed resistance by both methods and were ultimately classified as resistant, but the strain remained susceptible to 7 other tested antibiotics (Table 1).

Table 1. Antimicrobial susceptibility of Lactobacillus delbrueckii subsp. sunkii against 20 antibiotics (mean ± SD).

Type of drug Kirby–Bauer streaking method Zone of inhibition (diameter, mm) Dilution method MIC value

(µg/mL)
Results
ID/content (μg) Name ID Name
Oxazolidinones LNZ 30 Linezolid 40 ± 2 LNZ Linezolid ≤2 Sensitive
Quinolones CIP 5 Ciprofloxacin 18 ± 2 CIP Ciprofloxacin ≥2 –
Quinolones LVX 5 Levofloxacin 20 ± 2 LVX Levofloxacin 8 –
Quinolones GAT 5 Gatifloxacin 26 ± 2 – – – –
Tetracyclines TCY 30 Tetracycline 28 ± 2 TCY Tetracycline ≤1 –
Rifamycins RIF 5 Rifampicin 25 ± 2 RIF Rifampicin ≤0.5 –
Chloramphenicols CHL 30 Chloramphenicol 36 ± 2 – – – –
Penicillins AMP 10 Ampicillin 40 ± 1 AMP Ampicillin ≤0.25 Sensitive
Penicillins PEN 10 Penicillin 47 ± 2 PEN Penicillin ≤0.06 Sensitive
Glycopeptides VAN 30 Vancomycin 30 ± 1 VAN Vancomycin ≤1 Sensitive
Aminoglycosides GEN 10 Gentamicin 21 ± 2 GEN High-level gentamicin ≤500 –
Aminoglycosides AMK 30 Amikacin 22 ± 1 – – – –
Lincosamides CLI 2 Clindamycin 26 ± 1 CLI Clindamycin ≤0.25 Sensitive
Cephalosporins (3rd generation) CRO 30 Ceftriaxone 36 ± 1 CRO Ceftriaxone ≤0.5 –
Cephalosporins (4th generation) FEP 30 Cefepime 40 ± 1 – – – –
Cephalosporins (3rd generation) CTX 30 Cefotaxime 41 ± 2 – – – –
Macrolides ERY 15 Erythromycin 41 ± 2 ERY Erythromycin ≤0.25 Sensitive
Sulfonamides SXT 25 Trimethoprim/

Sulfamethoxazole
6 ± 0 SXT Trimethoprim/Sulfamethoxazole ≥4/76 Resistant
Carbapenems IPM 10 Imipenem 49 ± 2 – – – –
Carbapenems MEM 10 Meropenem 40 ± 1 MEM Meropenem ≤0.25 Sensitive

Note: “-” indicates that no result is available or the result cannot be determined.

16S rRNA gene alignment analysis

The 16S rRNA gene amplicon was sequenced by Sanger sequencing, and BLAST alignment against the NCBI database revealed 99.86% sequence identity to L. delbrueckii subsp. sunkii. The identified species was named L. delbrueckii subsp. sunkii WuYi 2021−1. The phylogenetic tree was constructed using the top 12 species with the highest sequence similarity in the database and is shown in S4 Fig. The bootstrap values for the upper and lower nodes of the phylogenetic tree are 10.9380% and 86.2646%, respectively, with only the lower node considered reliable (bootstrap value >70%). The tree shows that L. delbrueckii subsp. sunkii is phylogenetically related to five strains: L. delbrueckii subsp. sunkii NRIC 0767, L. delbrueckii subsp. sunkii CIRM BIA 266, L. delbrueckii subsp. indicus strain NCC 725, L. delbrueckii subsp. bulgaricus ATCC 11842 JCM 1002, and L. delbrueckii subsp. bulgaricus strain NBRC 13953.

Whole-genome sequencing results

A total of 1,906 coding genes were predicted from the whole-genome sequence (S2 Table). The numbers of annotated coding genes in the NR, KEGG, GO, COG, CAZy, Pfam, and Swiss-Prot databases were 1,888, 1,007, 1,232, 1,540, 216, 1,591, and 1,434, respectively. The COG database annotated a total of five genes: DnaA, DnaN, YbcJ, RecF, and GyrB. DnaA encodes an ATPase involved in DNA replication initiation; DnaN encodes the DNA polymerase sliding clamp subunit; YbcJ encodes an S4-like RNA-binding protein; RecF encodes a recombinational DNA repair ATPase (of the RecF pathway); and GyrB encodes the B subunit of type II topoisomerase (DNA gyrase/topo II, topoisomerase IV). These genes showed sequence identity ranging from 32.45% to 62.38% and all belong to the functional categories of DNA replication, recombination, and repair (S5 Fig). The CAZy database annotated genes in descending order of gene count: glycosyl transferases (GTs), glycoside hydrolases (GHs), carbohydrate-binding modules (CBMs), carbohydrate esterases (CEs), and auxiliary activities (AAs) with five related enzymes (S6 Fig). KEGG categorizes biological metabolic pathways into six major groups: Cellular Processes, Environmental Information Processing, Genetic Information Processing, Human Diseases, Metabolism, and Organismal Systems. Among these, the predominant category was Metabolism (S7 Fig). The GO annotation results cover three main categories: molecular function, biological process, and cellular component. Molecular function mainly includes catalytic activity, binding, and transporter activity. Biological process primarily encompassed metabolic process, cellular process, localization, biological regulation, and cellular component organization or biogenesis. Cellular component mainly refers to cell parts and protein-containing complexes (S8 Fig). The NR database annotated genes, including DNA polymerase III subunit beta, S4 domain-containing protein YaaA, DNA replication/repair protein RecF, and genes related to the ATP-hydrolyzing subunit B of DNA topoisomerase; based on the functions of these four genes, L. delbrueckii was the species with the highest annotation proportion (S9 Fig). Non-coding RNAs included 27 rRNAs, 94 tRNAs, and 27 other ncRNAs. Antibiotic resistance genes annotated using the CARD database are summarized in Fig 5. Additional analyses predicted 5 secretory proteins, 5 transmembrane proteins, 4 CRISPR arrays, and 1 prophage. The total number of raw bases generated by third-generation sequencing was 1,582,988,462 bp, the N content was 0.00%, and the number of sequences was 293,269. After assembly, the final genome size was 2,076,116 bp, with a GC content of 50.00%, an average sequencing depth of 705.62 × , 100% genome coverage, an N50 of 2,076,116 bp, and a BUSCO completeness of 98.5%. Comprehensive analysis results are summarized in S2 Table. The circular genome map in S10 Fig shows the genes, ncRNA, GC content, and repeat sequence data of L. delbrueckii subsp. sunkii.

Fig 5. CARD antibiotic resistance gene distribution.

Fig 5

Note: Pie chart segments colored by ARO (Antibiotic Resistance Ontology) categories, with segment sizes indicating relative gene proportions.

Virulence factor annotation results

A total of 1,906 predicted proteins from the L. delbrueckii subsp. sunkii strain were used as queries against the VFDB Set A and Set B protein databases. The searches yielded 4,266 initial hits from Set A and 15,263 from Set B, corresponding to 362 and 447 query proteins, respectively. Using strict filtering criteria (amino acid identity ≥ 80%, VFDB reference sequence coverage ≥ 70%, and E-value ≤ 1 × 10-5) [22], no homologs were detected in either dataset. Using extended criteria (40% ≤ amino acid identity < 80%, both query and reference coverage ≥ 70%, and E-value ≤ 1 × 10-5) [23], a total of 83 non-redundant VFDB homologs were identified. Of these, 42 were supported by both Set A and Set B, while 41 were supported only by Set B. Based on the best hits for each protein in Set B, VFDB functional classification was performed. The annotated homologs were mainly distributed across categories such as immune evasion/modulation, nutritional/metabolic factors, adhesion, regulation, and stress survival.

Discussion

According to the BioSample records in the NCBI Taxonomy Browser, the primary sources of the six subspecies of L. delbrueckii are as follows: L. delbrueckii subsp. sunkii [3,24,25] has been isolated predominantly from non-salted pickles and dairy products; L. delbrueckii subsp. bulgaricus [6,26] has been isolated from Bulgarian yogurt and kefir; L. delbrueckii subsp. delbrueckii has been found in fermented potatoes and cereal-based substrates; L. delbrueckii subsp. lactis [27] has been associated with milk and cheese production; L. delbrueckii subsp. indicus [28] has been isolated from dairy products; and L. delbrueckii subsp. jakobsenii [4] has been sourced from alcoholic fermented beverages. L. delbrueckii subsp. sunkii was first isolated in 2011 from Japanese non-salted pickles [3]. In 2021, we isolated this strain from the vaginal secretions of pregnant women. It was deposited in the China Center for Type Culture Collection (CCTCC) on August 5, 2022, under the accession number CCTCC M 20221248, and was designated as WuYi 2021−1. The whole-genome sequence was submitted to the NCBI database on October 23, 2022 (BioProject accession: PRJNA893246). Additionally, a Chinese invention patent was granted for this discovery (Patent No. ZL202210967911.6).

The L. delbrueckii subsp. sunkii isolated from Japanese non-salted pickles is a Gram-positive, non-spore-forming, facultatively anaerobic bacillus, typically 2.0–5.0 μm long, arranged singly, in pairs, or as short chains of 3–4 cells [3]. Kudo et al. [3] found that this strain grew weakly in MRS broth at 15 °C and showed no growth at 45 °C; on MRS agar under anaerobic incubation at 30 °C for 48 hours, colonies appeared cream-colored with smooth to rough surfaces, circular or irregular shapes, and diameters of 2–4 mm. Physiological traits: the optimal pH for growth is around 4.0; weak growth occurs in 4% NaCl. The strain is catalase-negative and produces acid from glucose without gas (final product: D-lactate) [3]. Ammonia is produced from L-arginine. Nitrate reduction is negative. Carbohydrate utilization: ferments fructose, mannose, mannitol, N-acetyl-D-glucosamine, cellobiose, maltose, melibiose, sucrose, D-trehalose, raffinose, gentiobiose, and salicin. Acid production is D-galactose-dependent. The strain hydrolyzes esculin [3]. In comparison, the L. delbrueckii subsp. sunkii strain that we isolated from the vaginal secretions of pregnant women appeared as Gram-positive short or long rods, which were non-flagellated and non-spore-forming. On modified blood agar, colonies are moist with smooth margins and slightly raised edges, show central depressions, and exhibit α-hemolysis. SEM reveals cells averaging 1–10 μm in length, resembling Cordyceps or silkworms. The surface of the bacterial cells was covered with a few filamentous fimbriae and white, spine-like fimbriae, and the cells were surrounded by filamentous fimbriae shed from the bacteria. Most cells exhibited a concave pore at one end. Biochemical characteristics: The hydrogen peroxide test was negative. The strain ferments dGLU, dMAL, dMNE, dMAN, SAC, and SAL but not dCEL, ProA, or CMT. The strain produces AGAL, AGLU, dSOR, ADH1, ADH2s, AlaA, APPA, and exhibits OPTO. These biochemical test results may be related to the function of GHs annotated for the bacterium in the CAZy database. GHs are enzymes that hydrolyze glycosidic bonds in various sugar-containing compounds, generating monosaccharides, oligosaccharides, or sugar complexes. Growth adaptation: The optimal growth temperature is 35 °C (close to human body temperature), and it thrives in blood medium containing 5% NaCl. Significant morphological and biochemical differences have been reported between subspecies strains from distinct sources, highlighting environmental adaptability.

The strain, when cultured on modified blood agar for 48 hours, exhibited a significant inhibitory effect on the growth of S. aureus and E. coli. Additionally, it formed a regular concentric α-hemolytic ring when co-cultured with S. aureus. We also observed that the growth of L. delbrueckii subsp. sunkii was inhibited by S. agalactiae in the culture medium. However, after producing a large amount of lactic acid, the strain in turn inhibited the growth of S. agalactiae. Kamble et al. [29] found that L. delbrueckii could inhibit the growth of hemolytic Staphylococcus, E. coli, and Enterococcus faecalis. Abedi et al. [30] reported that L. delbrueckii subsp. bulgaricus could inhibit E. coli infection in the intestine and exhibited anti-adhesion effects. The L. delbrueckii subsp. sunkii strain isolated from the human body tested negative in the hydrogen peroxide assay. However, it was capable of fermenting carbohydrates to produce acid, reducing the pH from 7.8 to around 4.0, thereby inhibiting the growth of pathogenic bacteria and preventing the overgrowth of opportunistic pathogens. This indicates a strong acid-producing capacity. Li et al. [31] discovered that the dapA, dapH, and lysC genes were the key factors contributing to the acid resistance of L. delbrueckii subsp. bulgaricus. Our previous research also found that the microbial population in the vaginal secretions of pregnant women was significantly lower than that of women with no history of sexual activity. A comparative analysis of strains revealed the absence of L. delbrueckii in the vaginal secretions of women with no history of sexual activity. This suggests that the bacterium may play an important role in vaginal self-cleaning and in maintaining the balance of vaginal microbiota. Additionally, the strain can lyse red blood cells in blood agar, forming an α-hemolytic ring, which may contribute to clearing residual menstrual blood in the vagina. The top 10 CARD-annotated antibiotic resistance genes in this strain were identified as those conferring resistance to macrolides, tetracyclines, peptides, lincosamides, glycopeptides, penams, fluoroquinolones, streptogramins, nitroimidazoles, and pleuromutilins. However, antibiotic susceptibility testing showed resistance only to sulfonamides, while the strain remained susceptible to 7 other commonly used antibiotics. This indicates a discrepancy between genotype and phenotype, which requires further experimental validation. These findings also suggest that most clinical antibiotics can negatively impact the growth and reproduction of L. delbrueckii subsp. sunkii, leading to a reduction in its population. This, in turn, could disrupt vaginal microbiota balance, potentially causing vaginitis and even affecting fetal development. Therefore, the use of antibiotics during pregnancy should be avoided. We followed the published WGS-based safety evaluation process for probiotic lactobacilli and applied strict screening thresholds. Initially, no virulence factors were annotated in the VFDB database, further suggesting that L. delbrueckii subsp. sunkii is a probiotic and non-pathogenic organism. Although annotations were found for immune modulation, nutritional/metabolic factors, adhesion, regulation, and stress survival, these annotations do not indicate pathogenicity; rather, they reflect positive immunomodulatory functions. For example, L. delbrueckii subsp. sunkii can inhibit the growth and reproduction of pathogenic bacteria by adhering to vaginal squamous epithelial cells, thereby exerting its adhesive function; it can also break down glycogen in vaginal epithelial cells to produce lactate, which contributes to its nutritional metabolic function [32]. The results of the antimicrobial susceptibility testing showed that gentamicin and amikacin (both aminoglycosides) may be sensitive to phenotype, which may be associated with the functions of glycosyltransferases (GTs) and glycoside hydrolases (GHs) annotated in the CAZy database. The core function of GTs is to catalyze glycosylation reactions. Glycoside antibiotics are glycosylated by glycosyltransferases in vivo, and the position, type, and number of glycosides have a significant impact on the activity of these antibiotics. Shani et al. [33] studied L. delbrueckii subsp. lactis and found that 52.1% of kanamycin minimum inhibitory concentrations (MICs), 9.9% of chloramphenicol MICs, and 5.6% of tetracycline MICs exceeded microbiological cutoffs (MCs). However, no antibiotic resistance genes (ARGs) were detected. De Jesus et al. [34] observed that L. delbrueckii subsp. lactis CIDCA 133 was resistant to streptomycin and gentamicin (both aminoglycosides), but the strain did not show hemolytic or mucin-degrading activity.

Different subspecies of L. delbrueckii have been reported to contribute to varying extents in clinical disease diagnosis, treatment, and industrial applications. Macho-Aizpurua et al. [35] reported a case of urinary tract-derived bacteremia caused by L. delbrueckii subsp. sunkii. Probiotics are known to modulate pathogen virulence; for instance, L. delbrueckii subsp. lactis CIDCA 133 may exert beneficial effects during Bacillus cereus infection of intestinal epithelial cells [36]. Wang et al. [37] demonstrated that L. delbrueckii subsp. bulgaricus LDSB-KSFY07 inhibits thrombosis in mice and reduces hepatic oxidative stress damage. The L. delbrueckii subsp. bulgaricus strain TCI904 mitigates high-fat diet-induced obesity in mice by regulating immune responses, improving metabolic profiles, and alleviating anxiety [38]. Ishikawa et al. [39] revealed that exopolysaccharides (EPS) produced by L. delbrueckii subsp. bulgaricus OLL1073R-1 prevented influenza virus infection, reduced secondary bacterial infection risks, and enhanced humoral immunity in influenza A-infected mice. However, this immune enhancement is suppressed by neuraminidase inhibitors such as oseltamivir [40]. Li et al. [41] identified nattokinase from L. delbrueckii subsp. bulgaricus as a potent thrombolytic agent in vitro, highlighting its potential for developing functional fermented dairy products. Hallajzadeh et al. [42] proposed L. delbrueckii subsp. lactis PTCC1057 as a promising candidate for future diabetes research.

Since the whole-genome sequences of L. delbrueckii subsp. sunkii currently recorded in gene databases are all derived from external environments, we conducted whole-genome sequencing to gain a comprehensive understanding of the nucleotide sequence of L. delbrueckii subsp. sunkii in the human body. A total of 1,906 coding genes were predicted from the whole-genome sequence. The numbers of annotated coding genes in the NR, KEGG, GO, COG, CAZy, Pfam, and Swiss-Prot databases were 1,888, 1,007, 1,232, 1,540, 216, 1,591, and 1,434, respectively. Additionally, we predicted 27 rRNA genes, 94 tRNA genes, and 27 other ncRNA genes. Furthermore, 5 secreted proteins, 5 transmembrane proteins, 4 CRISPR sequences, and 1 prophage were identified. The gene set identified for this bacterium in the COG, GO, and KEGG databases can be divided into two major functional modules: one module focuses on genetic information processing, including DNA replication, damage repair, and maintenance of genome homeostasis; the other part is involved in amino acid biosynthesis and has the potential to synthesize secondary metabolites such as β-lactams, providing a functional basis for subsequent analysis of the genetic and metabolic characteristics of the strain. The genes annotated in COG are mainly responsible for replication initiation, DNA damage repair and recombination, and maintenance of genome topology, playing a core role in ensuring genome stability. KEGG annotations indicate that some genes are mainly involved in amino acid biosynthesis, while others are involved in the synthesis of secondary metabolites. The signaling pathways and gene functions annotated in the KEGG and COG databases are primarily associated with metabolism, strongly suggesting that this bacterium functions as a probiotic in the human body. The BLAST alignment results from the NCBI database show a 99.86% sequence identity between our strain’s DNA sequences and those of L. delbrueckii subsp. sunkii, indicating that there are still some differences in the nucleotide sequences among strains from different sources. Sprotte et al. [43] isolated a novel L. delbrueckii subsp. bulgaricus phage, PMBT4, from fermented dairy products in Nigeria. The phage has a slender, non-contractile tail and an isometric head, indicating that it belongs to the family Siphoviridae. Similarly, we predicted a prophage in our strain, but its function and role remain unknown. Further research will be conducted to explore its gene functions in detail, laying the foundation for the development of L. delbrueckii subsp. sunkii microecological preparations.

Conclusions

The morphological characteristics, biochemical reactions, and nucleotide sequences of L. delbrueckii subsp. sunkii from different sources vary. Not all L. delbrueckii strains can produce H2O2, and L. delbrueckii subsp. sunkii has a strong capacity to ferment carbohydrates and produce acid. It is sensitive to most antibiotics, with a discrepancy between its genotype (resistance genes) and its phenotypic resistance profile. Sulfonamides do not affect the growth or reproduction of L. delbrueckii subsp. sunkii. We suggest that this strain may be associated with human metabolism and vaginal microbiota balance. Due to the limitations of in vitro experiments, animal studies are needed to further simulate the human vaginal environment. Therefore, animal model construction will be carried out in subsequent studies.

Supporting information

S1 Fig. Colony characteristics of Lactobacillus delbrueckii subsp. sunkii on modified blood agar.

(TIF)

pone.0363225.s001.tif (2.6MB, tif)
S2 Fig. Inhibition of Escherichia coli growth by Lactobacillus delbrueckii subsp. sunkii.

Note: A. Experimental group (E. coli colony diameter: 6 mm); B. Control group (E. coli colony diameter: 20 mm).

(TIF)

pone.0363225.s002.tif (370.1KB, tif)
S3 Fig. Inhibition of Staphylococcus aureus growth by Lactobacillus delbrueckii subsp. sunkii.

Note: A. Experimental group (S. aureus colony diameter: 4 mm); B. Control group (S. aureus colony diameter: 12 mm).

(TIF)

pone.0363225.s003.tif (447.7KB, tif)
S4 Fig. Phylogenetic tree.

Note: The branch length represents the evolutionary distance, with more closely related species positioned closer together on the phylogenetic tree. The branch length also reflects the degree of sequence differentiation among strains, with larger values indicating greater differentiation.

(TIFF)

pone.0363225.s004.tiff (9.3MB, tiff)
S5 Fig. COG functional classification of genes.

Note: X-axis: COG functional categories; Y-axis: number of annotated genes per category. Explanations for each category are provided on the right.

(TIF)

pone.0363225.s005.tif (232.3KB, tif)
S6 Fig. Distribution of CAZy families.

Note: X-axis: CAZy family classifications; Y-axis: gene counts.

(TIF)

pone.0363225.s006.tif (4.3MB, tif)
S7 Fig. KEGG pathway enrichment.

Note: Y-axis: secondary classifications of biological pathways; X-axis: gene counts. Colors represent primary pathway categories.

(TIF)

pone.0363225.s007.tif (4.2MB, tif)
S8 Fig. GO term distribution of target genes.

Note: Y-axis: GO terms; X-axis: gene counts. Colors distinguish Biological Process (BP), Cellular Component (CC), and Molecular Function (MF).

(TIF)

pone.0363225.s008.tif (2.7MB, tif)
S9 Fig. NR species distribution.

Note: Pie chart showing species proportions, with colors representing distinct taxa.

(TIF)

pone.0363225.s009.tif (13.7MB, tif)
S10 Fig. Genome atlas (Circos plot).

Note: Concentric circles display the following, from outermost to innermost: outermost circle: genomic coordinates; second circle: GC content; third circle: coding genes on the positive strand (red); fourth circle: coding genes on the negative strand (green); fifth circle: non-coding RNAs (ncRNAs) on the positive strand (blue); sixth circle: ncRNAs on the negative strand (purple); innermost circle: long repetitive sequences (orange).

(TIF)

pone.0363225.s010.tif (5.7MB, tif)
S1 Table. Primers for the 16S rRNA gene with P5 and P7 adapters.

(DOCX)

pone.0363225.s011.docx (12.4KB, docx)
S2 Table. Summary statistics of the analytical results.

(DOCX)

pone.0363225.s012.docx (12.9KB, docx)

Acknowledgments

We thank Professor Guanwu Li from the Department of Biochemistry and Molecular Biology at Shantou University Medical College for his help.

Abbreviations

CARD

Comprehensive Antibiotic Resistance Database

GN

Gram-negative

GP

Gram-positive

K-B

Kirby-Bauer

CLSI

Clinical and Laboratory Standards Institute

SEM

scanning electron microscopy

CCTCC

China Center for Type Culture Collection

MICs

minimum inhibitory concentrations

MCs

microbiological cutoffs

ARGs

antibiotic resistance genes

EPS

exopolysaccharides

ARO

Antibiotic Resistance Ontology

BP

biological process

CC

cellular component

MF

molecular function

Data Availability

The genome sequence was deposited in the NCBI database under accession number PRJNA893246 (https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA893246). The strain is preserved at CCTCC (No. CCTCC M 20221248). Supplementary figures and tables are provided in the online version.

Funding Statement

This work was supported by the Shenzhen Yantian District Science and Technology Innovation Bureau (No. YTWS 20230203). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Shah AB, Baiseitova A, Zahoor M, Ahmad I, Ikram M, Bakhsh A, et al. Probiotic significance of Lactobacillus strains: a comprehensive review on health impacts, research gaps, and future prospects. Gut Microbes. 2024;16(1):2431643. doi: 10.1080/19490976.2024.2431643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Tanigawa K, Watanabe K. Multilocus sequence typing reveals a novel subspeciation of Lactobacillus delbrueckii. Microbiology (Reading). 2011;157(Pt 3):727–38. doi: 10.1099/mic.0.043240-0 [DOI] [PubMed] [Google Scholar]
  • 3.Kudo Y, Oki K, Watanabe K. Lactobacillus delbrueckii subsp. sunkii subsp. nov., isolated from sunki, a traditional Japanese pickle. Int J Syst Evol Microbiol. 2012;62(Pt 11):2643–9. doi: 10.1099/ijs.0.037051-0 [DOI] [PubMed] [Google Scholar]
  • 4.Adimpong DB, Nielsen DS, Sørensen KI, Vogensen FK, Sawadogo-Lingani H, Derkx PMF, et al. Lactobacillus delbrueckii subsp. jakobsenii subsp. nov., isolated from dolo wort, an alcoholic fermented beverage in Burkina Faso. Int J Syst Evol Microbiol. 2013;63(Pt 10):3720–6. doi: 10.1099/ijs.0.048769-0 [DOI] [PubMed] [Google Scholar]
  • 5.Baek M-G, Kim KW, Yi H. Subspecies-level genome comparison of Lactobacillus delbrueckii. Sci Rep. 2023;13(1):3171. doi: 10.1038/s41598-023-29404-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dan T, Ren W, Liu Y, Tian J, Chen H, Li T, et al. Volatile Flavor Compounds Profile and Fermentation Characteristics of Milk Fermented by Lactobacillus delbrueckii subsp. bulgaricus. Front Microbiol. 2019;10:2183. doi: 10.3389/fmicb.2019.02183 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Akermann A, Weiermüller J, Christmann J, Guirande L, Glaser G, Knaus A, et al. Brewers’ spent grain liquor as a feedstock for lactate production with Lactobacillus delbrueckii subsp. lactis. Eng Life Sci. 2020;20(5-6):168–80. doi: 10.1002/elsc.201900143 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yue Y, Wang S, Lv X, Wang C, Xu B, Ping L, et al. Analysis of the complete genome sequence of Lactobacillus delbrueckii ssp. bulgaricus with post-acidification capacity and its influence on yogurt in storage. J Dairy Sci. 2022;105(2):1058–71. doi: 10.3168/jds.2021-20999 [DOI] [PubMed] [Google Scholar]
  • 9.Song Y, Zhao J, Liu W, Li W, Sun Z, Cui Y, et al. Exploring the industrial potential of Lactobacillus delbrueckii ssp. bulgaricus by population genomics and genome-wide association study analysis. J Dairy Sci. 2021;104(4):4044–55. doi: 10.3168/jds.2020-19467 [DOI] [PubMed] [Google Scholar]
  • 10.Mo J, Lu Y, Jiang S, Yan G, Xing T, Xu D, et al. Effects of the Probiotic, Lactobacillus delbrueckii subsp. bulgaricus, as a Substitute for Antibiotics on the Gastrointestinal Tract Microbiota and Metabolomics Profile of Female Growing-Finishing Pigs. Animals (Basel). 2022;12(14):1778. doi: 10.3390/ani12141778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Suda Y, Sasaki N, Kagawa K, Elean M, Zhou B, Tomokiyo M, et al. Immunobiotic Feed Developed with Lactobacillus delbrueckii subsp. delbrueckii TUA4408L and the Soymilk By-Product Okara Improves Health and Growth Performance in Pigs. Microorganisms. 2021;9(5):921. doi: 10.3390/microorganisms9050921 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Goo RY, Li MS. Proposal of Sphingobacterium allocomposti nom. nov., Mycobacterium chelonae subsp. bovistauri nom. nov. and Lactobacillus delbrueckii subsp. allosunkii nom. nov. as new names with replacement specific or subspecific epithets, respectively, for three illegitimate prokaryotic names Sphingobacterium composti Yoo et al. 2007, Mycobacterium chelonae subsp. bovis Kim et al. 2017 and Lactobacillus delbrueckii subsp. sunkii Kudo et al. 2012; proposal of Christiangramia oceanisediminis comb. nov. and Christiangramia crocea comb. nov. as replacement names respectively for two illegitimate prokaryotic names Gramella oceanisediminis Yang et al. 2023 and Gramella crocea Zhang et al. 2023. Int J Syst Evol Microbiol. 2024;74(4). doi: 10.1099/ijsem.0.006319 [DOI] [PubMed] [Google Scholar]
  • 13.Chin C-S, Alexander DH, Marks P, Klammer AA, Drake J, Heiner C, et al. Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data. Nat Methods. 2013;10(6):563–9. doi: 10.1038/nmeth.2474 [DOI] [PubMed] [Google Scholar]
  • 14.Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, Phillippy AM. Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. Genome Res. 2017;27(5):722–36. doi: 10.1101/gr.215087.116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chin C-S, Peluso P, Sedlazeck FJ, Nattestad M, Concepcion GT, Clum A, et al. Phased diploid genome assembly with single-molecule real-time sequencing. Nat Methods. 2016;13(12):1050–4. doi: 10.1038/nmeth.4035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, et al. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS One. 2014;9(11):e112963. doi: 10.1371/journal.pone.0112963 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hyatt D, Chen G-L, Locascio PF, Land ML, Larimer FW, Hauser LJ. Prodigal: prokaryotic gene recognition and translation initiation site identification. BMC Bioinformatics. 2010;11:119. doi: 10.1186/1471-2105-11-119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+: architecture and applications. BMC Bioinformatics. 2009;10:421. doi: 10.1186/1471-2105-10-421 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639–45. doi: 10.1101/gr.092759.109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Chen L, Zheng D, Liu B, Yang J, Jin Q. VFDB 2016: hierarchical and refined dataset for big data analysis--10 years on. Nucleic Acids Res. 2016;44(D1):D694-7. doi: 10.1093/nar/gkv1239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Buchfink B, Reuter K, Drost H-G. Sensitive protein alignments at tree-of-life scale using DIAMOND. Nat Methods. 2021;18(4):366–8. doi: 10.1038/s41592-021-01101-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.European Food Safety Authority EFSA. EFSA statement on the requirements for whole genome sequence analysis of microorganisms intentionally used in the food chain. EFSA J. 2024;22(8):e8912. doi: 10.2903/j.efsa.2024.8912 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Liu Y, Zheng H, Wang J, Xin J, Wu R, Zhang J, et al. Whole genome analysis and in vivo safety assessment of probiotic candidate Lactobacillus acidophilus L177. BMC Microbiol. 2025;25(1):398. doi: 10.1186/s12866-025-04099-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Güley Z, Fallico V, Cabrera-Rubio R, Cotter PD, Beresford T. Identification of Streptococcus infantarius subsp. infantarius as the species primarily responsible for acid production in Izmir Brined Tulum Cheese from the Aegean Region of Türkiye. Food Res Int. 2022;160:111707. doi: 10.1016/j.foodres.2022.111707 [DOI] [PubMed] [Google Scholar]
  • 25.Meloni MP, Piras F, Siddi G, Cabras D, Comassi E, Lai R, et al. Comparison of Activity of Commercial Protective Cultures and Thermophilic Lactic Acid Bacteria against Listeria monocytogenes: A New Perspective to Improve the Safety of Sardinian PDO Cheeses. Foods. 2023;12(6):1182. doi: 10.3390/foods12061182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Alexandraki V, Kazou M, Pot B, Tsakalidou E, Papadimitriou K. Complete genome sequence of the yogurt isolate Lactobacillus delbrueckii subsp. bulgaricus ACA-DC 87. Genome Announcements. 2017;5(34):e00868-17. doi: 10.1128/genomeA.00868-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.El Kafsi H, Binesse J, Loux V, Buratti J, Boudebbouze S, Dervyn R, et al. Lactobacillus delbrueckii ssp. lactis and ssp. bulgaricus: a chronicle of evolution in action. BMC Genomics. 2014;15(1):407. doi: 10.1186/1471-2164-15-407 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Dellaglio F, Felis GE, Castioni A, Torriani S, Germond J-E. Lactobacillus delbrueckii subsp. indicus subsp. nov., isolated from Indian dairy products. Int J Syst Evol Microbiol. 2005;55(Pt 1):401–4. doi: 10.1099/ijs.0.63067-0 [DOI] [PubMed] [Google Scholar]
  • 29.Kamble A, Naik S, Talathi M, Jadhav D, Pingale S, Kaul-Ghanekar R. Cervicovaginal microbiota isolated from healthy women exhibit probiotic properties and antimicrobial activity against pathogens isolated from cervical cancer patients. Arch Microbiol. 2022;204(8):491. doi: 10.1007/s00203-022-03103-5 [DOI] [PubMed] [Google Scholar]
  • 30.Abedi D, Feizizadeh S, Akbari V, Jafarian-Dehkordi A. In vitro anti-bacterial and anti-adherence effects of Lactobacillus delbrueckii subsp bulgaricus on Escherichia coli. Res Pharm Sci. 2013;8(4):260–8. [PMC free article] [PubMed] [Google Scholar]
  • 31.Li W, Yang L, Nan W, Lu J, Zhang S, Ujiroghene OJ, et al. Whole-genome sequencing and genomic-based acid tolerance mechanisms of Lactobacillus delbrueckii subsp. bulgaricus LJJ. Appl Microbiol Biotechnol. 2020;104(17):7631–42. doi: 10.1007/s00253-020-10788-5 [DOI] [PubMed] [Google Scholar]
  • 32.Mastromarino P, Brigidi P, Macchia S, Maggi L, Pirovano F, Trinchieri V, et al. Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J Appl Microbiol. 2002;93(5):884–93. doi: 10.1046/j.1365-2672.2002.01759.x [DOI] [PubMed] [Google Scholar]
  • 33.Shani N, Oberhaensli S, Berthoud H, Schmidt RS, Bachmann H-P. Antimicrobial Susceptibility of Lactobacillus delbrueckii subsp. lactis from Milk Products and Other Habitats. Foods. 2021;10(12):3145. doi: 10.3390/foods10123145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.de Jesus LCL, de Jesus Sousa T, Coelho-Rocha ND, Profeta R, Barroso FAL, Drumond MM, et al. Safety evaluation of Lactobacillus delbrueckii subsp. lactis CIDCA 133: a health-promoting bacteria. Probiotics Antimicrob Proteins. 2022;14(5):816–29. doi: 10.1007/s12602-021-09826-z [DOI] [PubMed] [Google Scholar]
  • 35.Macho-Aizpurua M, Angulo-López I, Arciniega-García JM, Díaz-de-Tuesta Del-Arco JL. Bacteriemia de origen urinario por Lactobacillus delbrueckii ssp. sunkii. Rev Esp Quimioter. 2021;34(4):400–1. doi: 10.37201/req/029.2021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rolny IS, Tiscornia I, Racedo SM, Pérez PF, Bollati-Fogolín M. Lactobacillus delbrueckii subsp lactis CIDCA 133 modulates response of human epithelial and dendritic cells infected with Bacillus cereus. Benef Microbes. 2016;7(5):749–60. doi: 10.3920/BM2015.0191 [DOI] [PubMed] [Google Scholar]
  • 37.Wang P, Tan F, Mu J, Chen H, Zhao X, Xu Y. Inhibitory Effect of Lactobacillus delbrueckii subsp. bulgaricus KSFY07 on Kappa-Carrageenan-Induced Thrombosis in Mice and the Regulation of Oxidative Damage. Cardiovasc Ther. 2022;2022:4415876. doi: 10.1155/2022/4415876 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lin Y-K, Lin Y-H, Chiang C-F, Yeh T-M, Shih W-L. Lactobacillus delbrueckii subsp. bulgaricus strain TCI904 reduces body weight gain, modulates immune response, improves metabolism and anxiety in high fat diet-induced obese mice. 3 Biotech. 2022;12(12):341. doi: 10.1007/s13205-022-03356-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Ishikawa H, Kuno Y, Kohda C, Sasaki H, Nagashima R, Iyoda M. Exopolysaccharides from Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 prevent influenza virus infection and attenuate secondary bacterial infection risk. Lett Appl Microbiol. 2022;74(5):632–9. doi: 10.1111/lam.13649 [DOI] [PubMed] [Google Scholar]
  • 40.Takahashi E, Sawabuchi T, Kimoto T, Sakai S, Kido H. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice. J Dairy Sci. 2019;102(11):9559–69. doi: 10.3168/jds.2019-16268 [DOI] [PubMed] [Google Scholar]
  • 41.Li C, Du Z, Qi S, Zhang X, Wang M, Zhou Y, et al. Food-grade expression of nattokinase in Lactobacillus delbrueckii subsp. bulgaricus and its thrombolytic activity in vitro. Biotechnol Lett. 2020;42(11):2179–87. doi: 10.1007/s10529-020-02974-2 [DOI] [PubMed] [Google Scholar]
  • 42.Hallajzadeh J, Eslami RD, Tanomand A. Effect of Lactobacillus delbrueckii Subsp. lactis PTCC1057 on Serum Glucose, Fetuin-A, and Sestrin 3 Levels in Streptozotocin-Induced Diabetic Mice. Probiotics Antimicrob Proteins. 2021;13(2):383–9. doi: 10.1007/s12602-020-09693-0 [DOI] [PubMed] [Google Scholar]
  • 43.Sprotte S, Fagbemigun O, Brinks E, Cho G-S, Casey E, Oguntoyinbo FA, et al. Novel Siphoviridae phage PMBT4 belonging to the group b Lactobacillus delbrueckii subsp. bulgaricus phages. Virus Res. 2022;308:198635. doi: 10.1016/j.virusres.2021.198635 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

António Machado

18 Jul 2026

Analysis of Biological Characteristics and Gene Function of Lactobacillus delbrueckii subsp. sunkii

PLOS One

Dear Dr. Wu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 31 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

António Machado

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. The ethical approval number(s) listed in the manuscript and submission metadata (YTWS 20230203) does not match the approval number on the ethical approval document you provided. Please ensure that all approval numbers are correct.

3. Thank you for stating the following financial disclosure:

“This work was supported by the Shenzhen Yantian District Science and Technology Innovation Bureau (No. 20230203).”

Please state what role the funders took in the study.  If the funders had no role, please state: 'The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.'

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

5. Please note that your Data Availability Statement is currently missing the repository name and/or the DOI/accession number of each dataset OR a direct link to access each database. If your manuscript is accepted for publication, you will be asked to provide these details on a very short timeline. We therefore suggest that you provide this information now, though we will not hold up the peer review process if you are unable.

6. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

8. Please upload a new copy of Figure S7 as the detail is not clear. Please follow the link for more information:  https://journals.plos.org/plosone/s/figures.

9. Please include a copy of Table 1, 2 and 3 which you refer to in your text on page 9.

10. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments:

Dear authors,

I am pleased to say that both reviewers enjoyed the manuscript very much and we are excited about the possibility of publishing your work. However, both reviewers recommended several improvements to the original manuscript. Please read carefully both reviewers’ reports addressing and answering all comments and suggestions.

So, I kindly invite the authors to realize a thoughtful revision of the submitted manuscript to achieve publication endorsement by the reviewers.

Thank you and best regards,

António Machado

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: No

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?-->?>

Reviewer #1: I Don't Know

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: No

Reviewer #2: Yes

**********

Reviewer #1: The study “Analysis of Biological Characteristics and Gene Function of Lactobacillus delbrueckii subsp. sunkii” is significant for the research and characterization of probiotics and underscores its importance by describing a little-known subspecie; however, the manuscript lacks detail and specific information regarding the work performed. Therefore, the following major changes are suggested:

- The “Methods and Results” section of the abstract does not specify the methods used and focuses more on describing the results. Please rewrite the abstract appropriately.

- Check the correct spelling of genera and species throughout the manuscript. On lines 54 and 55, it is written “L. delbrueckii subsp. Delbrueckii” and “L. delbrueckii subsp. Indicus.”

- The introduction is very short and lacks important details on the topic. Please expand the information.

- Restructure the objectives at the end of the introduction. Phrases such as “lays a solid theoretical foundation…” or “At present, our research results have entered the stage of transforming…” should not be part of the objectives..

- Begin the Methods and Materials section with the ethics section and the project’s approval by the ethics committee.

- Explain the sampling process in greater detail. Specify the vaginal sites from which the sample was taken, the brand of swabs used, etc.

- The methods are not described in sufficient detail. For example, the process used to analyze the strains by electron microscopy is not explained (how were the samples prepared? How were they observed? How were images captured? What equipment or instruments were used?). The same applies to Microflex LT/SH and most of the other procedures

- In line 116, the phrase “results were observed” does not specify anything. Please properly separate each procedure and explain how the results were observed, what was measured, or what was quantified

- Even if you followed the manufacturer’s instructions, briefly explain how the DNA extraction was performed and how it was quantified

- Each procedure should be detailed more or less as in lines 125–130, although here it is also unclear how the results were verified (was it by electrophoresis?)

- Please carefully review the Methods and Materials section and provide all necessary information to support the reproducibility of your procedures

- Provide the bibliographic reference for where the terms “cordyceps” or “silkworm” were obtained to describe Lactobacillus in microscopic images

- Do Tables 1 and 2 detail results for a single strain? If only one row was included because the results are the same across the 15 strains analyzed, it is not necessary to create tables; rather, this could be explained in the text.

- In line 191, what is the difference between “antibacterial” and “antibiotic,” and why are these two terms used in the subsection if they are synonyms?

- Line 192 should be included in the Materials and Methods section.

- Lines 193 and 194 report pH measurements; how were these measurements taken? This should be detailed in the Materials and Methods section.

- Figures S2 and S3 are labeled A and B, but the figure captions do not specify what each letter means. Additionally, indicate the inhibition zone that was measured, as no inhibition halos are visible in the figure.

- Include the phylogenetic tree used to identify the sequenced strains and provide a more detailed description of the results obtained.

- Was the whole genome of a single strain sequenced? If so, explain how this strain was chosen

- The results do not present the findings from the quality analysis of the whole genomes (the interpretation of results depends on this)

- The description of results is too concise. Details of each result should be provided alongside its corresponding figure

- Line 213 states, “The genome atlas is illustrated in S9 Fig,” but what does this genome atlas represent? How is it interpreted? And what are the most relevant results? This should be specified for all results found in the study.

- The results should be reviewed and improved to better align them with the discussion. The information also needs to be better supported, as the entire manuscript contains only 28 references, and given the significance of the results, there should be many more.

It is important to improve the manuscript as a whole in order to present the findings clearly and in detail. Congratulations on your work; it would undoubtedly be a great contribution with several improvements that can be made.

Reviewer #2: This is an interesting topic. While I believe that this article is indeed an important addition to the limited existing literature on this topic. However, there are some major revision that need to be addressed.

The abstract is not properly structured and should be revised to clearly present the background, objectives, methodology, key results, and conclusions.

The Introduction section requires substantial improvement. It is too brief and does not provide sufficient background on the study topic. The authors should include relevant references to previous studies to establish the current state of knowledge, identify existing research gaps, and better justify the rationale and significance of the present study. Lactobacillus delbrueckii subsp. sunkii is a subspecies of the lactic acid bacterium Lactobacillus delbrueckii. Its role is not described.

The sample size is relatively small, with only 15 pregnant women recruited for the study, which may limit the generalizability of the findings. The authors should provide a clear justification for selecting pregnant women at the specified gestational age. Additionally, the manuscript lacks clearly defined inclusion and exclusion criteria, which are essential for understanding the study population and ensuring reproducibility. Furthermore, several abbreviations are used without first defining their full forms. All abbreviations should be written out in full at their first occurrence in the manuscript.

Specify the exact PacBio Sequel chemistry and Illumina HiSeq model used (e.g., HiSeq 2500, HiSeq X Ten).

Cite the software and databases (HGAP4, Canu, Falcon, Pilon, Prodigal, Circos, etc.) in the reference list.

Clarify which assembly software generated the final assembly, since three assemblers (HGAP4, Falcon, and Canu) are mentioned.

If available, report assembly quality metrics (e.g., sequencing depth, N50, completeness, and BUSCO score) to better support the genome assembly quality.

The authors should specify which glucose assay was used to measure glucose consumption.

Report the mean ± standard deviation (or standard error) for glucose concentration and pH rather than approximate values.

The antibacterial assay should include the method used (e.g., agar well diffusion, spot-on-lawn, or disk diffusion), the diameter of inhibition zones (mm), and the number of biological replicates.

Specify which sulfonamide antibiotic was tested (e.g., sulfamethoxazole or trimethoprim–sulfamethoxazole), as "sulfonamides" refers to a class of antibiotics.

Include the interpretive criteria or guidelines (e.g., CLSI or EFSA recommendations for lactic acid bacteria) used to classify isolates as susceptible or resistant.

The authors should provide the genome assembly statistics, including genome size, GC content, sequencing depth/coverage, N50 value, and completeness assessment.

The term "70 CRISPR arrays" requires clarification, as this number appears unusually high for many bacterial genomes; the authors should specify whether these represent complete CRISPR loci or predicted repeat elements.

The annotation results should clarify whether gene counts from different databases represent unique genes or overlapping annotations.

The identification of "microRNA" in a bacterial genome should be carefully verified and explained, as microRNAs are primarily associated with eukaryotic systems.

A phylogenetic tree based on 16S rRNA or whole-genome comparisons (e.g., ANI or digital DNA–DNA hybridization) would strengthen species-level identification.

The discussion needs revision.

The statement that the strain was "sourced from alcoholic fermentation beverages" requires a supporting reference or clarification, as the subsequent sentence states that the species was first isolated from Japanese salt-free pickles.

The authors should avoid using "we first isolated" unless this is supported by a comprehensive literature search demonstrating novelty.

If the strain was isolated from vaginal secretions, the manuscript should provide ethical approval information, informed consent details, and inclusion criteria for the donor population.

The relationship between the vaginal isolate and potential probiotic/functional significance should be discussed carefully, avoiding conclusions beyond the available evidence.

The authors should clarify whether the phenotypic characteristics listed in the first paragraph are derived from the original type strain description or from the current isolate.

The comparison between the pickle-derived strain and the vaginal isolate should include additional comparative data (e.g., growth conditions, biochemical profiles, genome-level differences) rather than only cell morphology.

The term "D-lactate" should be supported by the analytical method used for lactate isomer determination.

If this section describes the newly isolated vaginal strain, provide complete phenotypic characterization rather than only morphological observations.

The statement that the strain "thrives in blood medium containing 5% NaCl" requires clarification because blood medium and NaCl tolerance represent different physiological tests.

The authors should distinguish between experimentally measured phenotypes and genome-predicted functions to avoid overinterpretation.

Safety assessment should include additional analyses, such as virulence factor screening and antibiotic resistance gene evaluation, particularly for a strain isolated from human samples.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Nov 18;21(11):e0363225. doi: 10.1371/journal.pone.0363225.r002

Author response to Decision Letter 1


3 Sep 2026

António Machado, PhD

Academic Editor

plos one

Dear António Machado:

We would like to express our sincere gratitude for your and the reviewers’ valuable input on our manuscript (ID: PONE-D-26-06910), which we have revised in accordance with the reviewer’s remarks. We hereby resubmit a revised version of our manuscript for further consideration for publication in plos one.

We have responded to each of the reviewers’ comments in a point-by-point manner. In addition, we have provided a revised version of the manuscript with changes indicated in red font. We hope that the changes incorporated into the revised manuscript satisfactorily address the reviewers’ concerns.

In addition to revising the manuscript according to the reviewers' suggestions, we have carefully re-examined the entire text and corrected minor errors (including, but not limited to: punctuation, spacing, and other typographical issues), which have been highlighted in red.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response #1: We have formatted the manuscript according to the journal's template and highlighted all revisions in red. However, we noticed that some recently published articles do not fully match the template, so we are uncertain whether additional formatting adjustments are needed. We would greatly appreciate your advice. Thank you.

2.The ethical approval number(s) listed in the manuscript and submission metadata (YTWS 20230203) does not match the approval number on the ethical approval document you provided. Please ensure that all approval numbers are correct.

Response #2: We have unified the approval number across the funding and ethics approval documents as No. YTWS 20230203.

3. Thank you for stating the following financial disclosure:

“This work was supported by the Shenzhen Yantian District Science and Technology Innovation Bureau (No. 20230203).”

Please state what role the funders took in the study. If the funders had no role, please state: 'The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.'

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Response #3: This work was supported by the Shenzhen Yantian District Science and Technology Innovation Bureau (No. YTWS 20230203). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and their sole contribution was providing research funding.

4. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

Response #4: We have removed all the text related to funding from the article.

5. Please note that your Data Availability Statement is currently missing the repository name and/or the DOI/accession number of each dataset OR a direct link to access each database. If your manuscript is accepted for publication, you will be asked to provide these details on a very short timeline. We therefore suggest that you provide this information now, though we will not hold up the peer review process if you are unable.

Response #5: We have added a direct link to the database in the data availability statement (marked in red): "The raw sequencing data have been deposited at NCBI under accession number PRJNA893246 ("https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA893246)."

6.When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

Response #6: The whole genome data of Lactobacillus delbrueckii subsp. sunkii have been deposited in the NCBI BioProject database and are accessible under accession number PRJNA893246 (https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA893246).

7.Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Response #7: We have added the following statement at lines 110-113 of the Materials and Methods section as requested: "This project was approved by the Ethics Committee of Shenzhen Yantian District People’s Hospital and the Health Bureau of Yantian District, Shenzhen (No. YTWS 20230203). The study was conducted with the informed consent of the patients and in accordance with the principles of the Declaration of Helsinki."

8.Please upload a new copy of Figure S7 as the detail is not clear. Please follow the link for more information:  https://journals.plos.org/plosone/s/figures.

Response #8: We have replaced the original Figure S7 with a clear Figure S8 as requested.

Figure S8

9.Please include a copy of Table 1, 2 and 3 which you refer to in your text on page 9.

Response #9: As suggested by Reviewer 1, we have removed Tables 1 and 2 and incorporated their contents into the text of the Results section, as the data are more concisely presented in narrative form. Consequently, the original Table 3 has been renumbered as Table 1.

10. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Response #10: We have revised the manuscript according to the journal's requirements and have marked all revisions in red.

Reviewer 1

The study “Analysis of Biological Characteristics and Gene Function of Lactobacillus delbrueckii subsp. sunkii” is significant for the research and characterization of probiotics and underscores its importance by describing a little-known subspecie; however, the manuscript lacks detail and specific information regarding the work performed. Therefore, the following major changes are suggested:

Comment #1: The “Methods and Results” section of the abstract does not specify the methods used and focuses more on describing the results. Please rewrite the abstract appropriately.

Response #1: In response to the reviewers’ comments, we have revised the abstract by adding the methodological details in lines 28–36, which are now highlighted in red.

Comment #2: Check the correct spelling of genera and species throughout the manuscript. On lines 54 and 55, it is written “L. delbrueckii subsp. Delbrueckii” and “L. delbrueckii subsp. Indicus.”

Response #2: We thank the reviewer for pointing out these errors. We have corrected the spelling of L. delbrueckii subsp. delbrueckii and L. delbrueckii subsp. indicus (originally incorrectly capitalized as "Delbrueckii" and "Indicus" in lines 54–55) to lowercase. The revisions have been highlighted in red in the revised version (lines 61–62), and we have also carefully checked the entire manuscript for similar nomenclature errors.

Comment #3: The introduction is very short and lacks important details on the topic. Please expand the information.

Response #3: We have added relevant information and cited the latest literature on lines 63–80, 82-93, and 95–106 of the Introduction section, as suggested by the reviewers.

Comment #4: Restructure the objectives at the end of the introduction. Phrases such as “lays a solid theoretical foundation…” or “At present, our research results have entered the stage of transforming…” should not be part of the objectives..

Response #4: We have restructured the research objectives at the end of the Introduction based on the reviewers' opinions, and we have also made revisions to and deletions of inappropriate wording.

Comment #5: Begin the Methods and Materials section with the ethics section and the project’s approval by the ethics committee.

Response #5: In accordance with the opinions of the reviewing experts, we have added an ethics statement and project approval from the ethics committee in lines 110–113 of the Methods and Materials section.

Comment #6: Explain the sampling process in greater detail. Specify the vaginal sites from which the sample was taken, the brand of swabs used, etc.

Response #6: Based on the reviewers' comments, we have revised lines 123–125 of the 'Sample collection and isolation' section.

Comment #7: The methods are not described in sufficient detail. For example, the process used to analyze the strains by electron microscopy is not explained (how were the samples prepared? How were they observed? How were images captured? What equipment or instruments were used?). The same applies to Microflex LT/SH and most of the other procedures.

Response #7: We have supplemented the Methods section (lines 132–147) based on the reviewers' comments and have highlighted the changes in red.

Comment #8: In line 116, the phrase “results were observed” does not specify anything. Please properly separate each procedure and explain how the results were observed, what was measured, or what was quantified.

Response #8: In response to the reviewers' comments, we have revised the relevant content containing the phrase "results were observed" in line 116 and have highlighted the changes in red in lines 172–180 of the revised manuscript.

Comment #9: Even if you followed the manufacturer’s instructions, briefly explain how the DNA extraction was performed and how it was quantified.

Response #9: We have supplemented the DNA extraction and quality inspection in lines 185-203 of the manuscript according to the opinions of the reviewers, and marked them in red.

Comment #10: Each procedure should be detailed more or less as in lines 125–130, although here it is also unclear how the results were verified (was it by electrophoresis?)

Response #10: We thank the reviewers for their concerns. We verified the DNA integrity by agarose gel electrophoresis, and the results are briefly described in lines 215-220 of the manuscript.

Comment #11: Please carefully review the Methods and Materials section and provide all necessary information to support the reproducibility of your procedures.

Response #11: We have carefully reviewed the content of the Methods and Materials section in response to the reviewers' comments to ensure the reproducibility of the experimental procedures. The revised sections have been marked in red.

Comment #12: Provide the bibliographic reference for where the terms “cordyceps” or “silkworm” were obtained to describe Lactobacillus in microscopic images.

Response #12: We thank the reviewer for their thoughtful comments. The terms "Cordyceps" and "silkworm" are used by the authors to describe bacterial morphology under SEM, and no specific references are cited for these descriptive terms. Nevertheless, I can provide physical images of these "Cordyceps" or "silkworm" morphologies for the reviewer's reference.

Pictures of Cordyceps sinensis

Pictures of silkworm

Morphological characteristics of Lactobacillus delbrueckii subsp. sunkii under scanning electron microscopy

Comment #13: Do Tables 1 and 2 detail results for a single strain? If only one row was included because the results are the same across the 15 strains analyzed, it is not necessary to create tables; rather, this could be explained in the text.

Response #13: We thank the reviewers for their suggestions. Accordingly, we have deleted Tables 1 and 2 and revised the relevant content in lines 304–313 of the Results section (main text), with the changes marked in red. During the revision, we discovered that, owing to an oversight in the initial draft, We had mistakenly used the GP and GN results from another strain of Lactobacillus delbrueckii subsp. indicus. We have corrected this and sincerely apologize for the error.

Comment #14: In line 191, what is the difference between “antibacterial” and “antibiotic,” and why are these two terms used in the subsection if they are synonyms?

Response #14: We thank the reviewer for raising these concerns. "antimicrobial" encompasses both bactericidal and bacteriostatic actions, whereas "antibiotic" is used in this article specifically to refer to antibiotic susceptibility disks. The vast majority of researchers use "antibacterial activity" to describe the inhibitory effects of their metabolites, unless the substance has been clearly identified as a bacteriocin or an antibiotic compound. Furthermore, "antimicrobial susceptibility" is a standard term in this field, referring specifically to the growth inhibition of bacteria by clinically approved antibiotics. Thus, the two terms are not interchangeable. We hope this clarifies the issue. Accordingly, We have uniformly revised the relevant terms to "antibacterial activity" and "antimicrobial susceptibility" throughout the manuscript and marked them in red.

Comment #15: Line 192 should be included in the Materials and Methods section.

Response #15: We have incorporated the content of line 192 of the original manuscript into lines 156-159 and 172–180 of the Materials and Methods section in accordance with the reviewers' suggestions, and these changes have been marked in red.

Comment #16: Lines 193 and 194 report pH measurements; how were these measurements taken? This should be detailed in the Materials and Methods section.

Response #16: We thank the reviewer for the suggestions. Accordingly, we have added the relevant content and marked it in red in lines 172–180 of the Materials and Methods section.

Comment #17: Figures S2 and S3 are labeled A and B, but the figure captions do not specify what each letter means. Additionally, indicate the inhibition zone that was measured, as no inhibition halos are visible in the figure.

Response #17: We have indicated the meanings of letters A and B in Figures S2 and S3, which are highlighted in red in lines 793–798 of the manuscript. A and B measured the diameter of colonies of reference strains of Escherichia coli and Staphylococcus aureus, rather than the inhibition zone. Because the inhibition zone is overlapped by the α-hemolytic zone and cannot be clearly seen when photographed against a red background, it can only be visualized by light transmission from the back of the plate. To capture images of the inhibition zone, we performed the experiment a second time.

The green circle indicates the zone of inhibition on the backlit surface of the blood culture medium (visible only under transmitted light).

Comment #18: Include the phylogenetic tree used to identify the sequenced strains and provide a more detailed description of the results obtained.

Response #18: Following the reviewers' suggestions, we have included a new Figure S4 (Phylogenetic Tree). Accordingly, we have added relevant text to lines 240–243 (Methods) and 327–336 (Results), with the changes highlighted in red.

Figure S4 Phylogenetic tree

Comment #19: Was the whole genome of a single strain sequenced? If so, explain how this strain was chosen.

Response #19: Yes, this strain was screened using 16S rRNA gene sequencing. After Sanger sequencing of the amplified 16S rRNA gene product, BLAST alignment against the NCBI database showed that the DNA sequence was 99.86% identical to Lactobacillus delbrueckii subsp. sunkii. In addition, the morphological and biochemical characteristics of this strain were consistent with those of other strains, indicating that this strain is representative. I hope my answer can address the concerns of the reviewers.

Comment #20: The results do not present the findings from the quality analysis of the whole genomes (the interpretation of results depends on this).

Response #20: We have now added whole-genome quality analysis data at lines 369–373 of the Results section, as suggested by the reviewers, and have highlighted these revisions in red in the revised manuscript.

Comment #21: The description of results is too concise. Details of each result should be provided alongside its corresponding figure.

Response #21: We thank the reviewer for the valuable comments. To avoid redundancy between the figures/tables and the textual descriptions, we have presented some of the detailed descriptions in the Results as requested and highlighted the changes in red (lines 327–375).

Comment #22: Line 213 states, “The genome atlas is illustrated in S9 Fig,” but what does this genome atlas represent? How is it interpreted? And what are the most relevant results? This should be specified for all results found in the study.

Response #22: Thank you very much for the reviewer's suggestions. Due to the addition of S4 Fig, the S9 Fig mentioned in line 213 of the original article has been changed to S10. The genome map is mainly a visual display of the overall structure of the bacterial genome, and it represents all the genomic information of the entire bacterial chromosome. The genome map displays seven types of information from the outside in, as follows: the outermost circle shows genomic coordinates; the second circle shows GC content; the third circle shows coding genes on the positive strand (red); the fourth circle shows coding genes on the negative strand (green); the fifth circle shows non-coding RNAs (ncRNAs) on the positive strand (blue); the sixth circle shows ncRNAs on the negative strand (purple); and the innermost circle shows long repetitive sequences (orange). We have annotated Fig 10 accordingly. The most relevant result is that the bacterial chromosome possesses a circular genome, as illustrated in the circular map, and this map provides information on genes, ncRNAs, GC content, and repetitive sequences. Since the content of Figs S4–S10 has increased significantly, we are concerned that the word count of the revised manuscript may exceed the limit. Therefore, this relevant content is included in the figure caption and marked in red on lines 817–821 of the manuscript.

Comment #23:The results should be reviewed and improved to better align them with the discussion. The information also needs to be better supported, as the entire manuscript contains only 28 references, and given the significance of the results, there should be many more.

It is important to improve the manuscript as a whole in order to present the findings clearly and in detail. Congratulations on your work; it would undoubtedly be a great contribution with several improvements that can be made.

Response #23: We have revised the results section according to the opinions of the reviewers, expanded the discussion section accordingly, and cited 15 references. All modified content is marked in red.

Reviewer 2

This is an interesting topic. While I believe that this article is indeed an important addition to the limited existing literature on this topic. However, there are some major revision that need to be addressed.

Comment #1: The abstract is not properly structured and should be revised to clearly present the background, objectives, methodology, key results, and conclusions.

Response #1: We are grateful to the reviewers for pointing out this issue, which was also raised by another reviewer. We have revised the corresponding text (lines 28–36 and 49–55) in accordance with both reviewers' suggestions and have highlighted the changes in red.

Comment #2: The Introduction section requires substantial improvement. It is too brief and does not provide sufficient background on the study topic. The authors should include relevant references to previous studies to establish the current state of knowledge, identify existing research gaps, and better justify the rationale and significance of the present study. Lactobacillus delbrueckii subsp. sunkii is a subspecies of the lactic acid bacterium Lactobacillus delbrueckii. Its role is not described.

Response #2: We have added relevant information and cited the latest literature on lines 63–80, 82-93, and 98–106 of the Introduction section, as suggested by the reviewers.

Comment #3: The sample size is relatively small, with only 15 pregnant women recruited for the study, which may limit the generalizability of the findings. The authors should provide a clear justification for selecting pregnant women at the specified gestational age. Additionally, the manuscript lacks clearly defined inclusion and exclusion criteria, which are essential for understanding the study population and ensuring reproducibility. Furthermore, several abbreviations are used without first defining their full forms. All abbreviations should be written out in full at their first occurrence in the manuscript.

Response #3: We fully understand the reviewers' concerns. We chose a gestational age of 35 ± 4 weeks because previous experimental studies found significant differences among Lactobacillus delbrueckii species in the vaginal secretions of late pregnant women (https://link.cnki.net/doi/10.13381/j.cnki.cjm.201909004). To ensure transparency, we have clearly defined the inclusion and exclusion criteria, as well as the definition of the third trimester of pregnancy, in the "Study subjects" section of our manuscript and have highlighted these revisions in red. In addition, we carefully checked the abbreviations throughout the text to ensure that their full names are provided when they first appear, and the modified content is marked in red.

Comment #4: Specify the exact PacBio Sequel chemistry and Illumina HiSeq model used (e.g., HiSeq 2500, HiSeq X Ten).

Response #4: We have revised lines 230–232 of the manuscript and highlighted the changes in red in response to the reviewers' comments.

Comment #5: Cite the software and databases (HGAP4, Canu, Falcon, Pilon, Prodigal, Circos, etc.) in the reference list.

Response #5: We sincerely appreciate the reviewers' comments. In accordance with their suggestions, we have incorporated the necessary citations for the software and databases used, and have added references 13–19 accordingly.

Comment #6: Clarify which assembly software generated the final assembly, since three assemblers (HGAP4, Falcon, and Canu) are mentioned.

Response #6: Three assembly software packages (HGAP4, Falcon, and Canu) were used, and we have revised lines 255–257 of the manuscript and highlighted them in red to address the reviewers' concerns.

Comment #7: If available, report assembly quality metrics (e.g., sequencing depth, N50, completeness, and BUSCO score) to better support the genome assembly quality.

Response #7: In response to the reviewers' comments, we have added assembly quality metrics in the revised manuscript (lines 369–373) and have highlighted these additions in red for easy identification.

Comment #8: The authors should specify which glucose assay was used to measure glucose consumption.

Response #8: Glucose was measured using the hexokinase method. We have revised the manuscript and highlighted the changes in red in lines 174–176 in response to the reviewers' comments.

Comment #9: Report the mean ± standard deviation (or standard error) for glucose concentration and pH rather than approximate values.

Response #9: We have revised line 318 of the manuscript and highlighted the changes in red in response to the reviewers' comments.

Comment #10: The antibacterial assay should include the method used (e.g., agar well diffusion, spot-on-lawn, or disk diffusion), the diameter of inhibition zones (mm), and the number of biological replicates.

Response #10: We thank the reviewers for their valuable suggestions. As requested, we have revised lines 158-159 and 178-180 of the manuscript. The sentence now reads: "The antibacterial test was repeated three times using the spot-on-lawn method," and the change has been marked in red.

Comment #11: Specify which sulfonamide antibiotic was tested (e.g., sulfamethoxazole or trimethoprim–sulfamethoxazole), as "sulfonamides" refers to a class of antibiotics.

Response #11: In the "Name" column of the third-to-last row of the original Table 3 (now Table 1), the entry reads "Trimethoprim/sulfamethoxazole." We have highlighted this revision in red.

Comment #12: Include the interpretive criteria or guidelines (e.g., CLSI or EFSA recommendations for lactic acid bacteria) used to classify isolates as susceptible or resistant.

Response #12: We thank the reviewers for their valuable comments. At lines 170-172 of the manuscript, we have cited the Clinical and Laboratory Standards Institute (CLSI) M45, 3rd Edition.

Comment #13: The authors should provide the genome assembly statistics, including genome size, GC content, sequencing depth/coverage, N50 value, and completeness assessment.

Response #13: In response to the reviewers' comments, we have added assembly quality metrics in the revised manuscript (lines 369–373) and have highlighted these additions in red for easy identification: " The total number of raw bases generated by third-generation sequencing was 1,582,988,462 bp, the N content was 0.00%, and the number of sequences was 293,269. After assembly, the final genome size was 2,076,116 bp, with a GC content of 50.0%, an average sequencing depth of 705.62×, 100% genome coverage, an N50 of 2,076,116 bp, and a BUSCO completeness of 98.5%(Single-copy value is 97.8%,Duplicated value is 0.7%,Fragmented value is 0.7%,Missing value is 0.7%).” Because a complete bacterial genome consists of a single contig, the assembled genome size is equal to the N50 value. The results of PacBio sequencing data quality assessment and assembly-related analyses are presented in the following figures:

BUSCO completeness score raw data

Third-generation sequencing read length distribution plot

Note: The horizontal axis represents the read length (bp), and the vertical axis shows the density distribution of reads.

GC content versus sequencing depth association plot

Note: The x-axis represents the GC content, and the y-axis represents the average read coverage depth. The upper and right histograms show the distributions of GC content and sequencing depth, respectively. This plot is used to assess GC bias in the sequencing data. In the absence of significant GC bias, the scatter plot should approximate a Poisson-like distribution, with a peak near the genomic GC content and decreasing coverage depth as GC content deviates from the peak.

Comment #14: The term "70 CRISPR arrays" requires clarification, as this number appears unusually high for many bacterial genomes; the authors should specify whether these represent complete CRISPR loci or predicted repeat elements.

Response #14: We thank the reviewer for spotting this error. I had mistakenly written the total number of repeats as 70 CRISPRs, and have corrected it to 4 CRISPRs on lines 368 and 527 of the manuscript, marked in red. We predicted a total of 4 CRISPR arrays in L. delbrueckii subsp. sunkii. These arrays are distributed across four distinct genomic intervals: two small arrays (each containing three repeats) are closely located near the 60 kb region, separated by only ~70 bp; the other two arrays are situated at approximately 823 kb (containing 55 repeats, spanning ~3.6 kb) and 1.79 Mb (containing 9 repeats), respectively.

Comment #15: The annotation results should clarify whether gene counts from different databases represent unique genes or overlapping annotations.

Response #15: Thank you very much for pointing out this issue. Due to inaccurate previous statements, we have made corrections and highlighted them in red in lines 338-341 of the Results section. The total number of coding genes predicted by the whole-genome sequence is 1,906 (S2 Table). The numbers of annotated coding genes in the NR, KEGG, GO, COG, CAZy, Pfam, and Swiss-Prot databases were 1,888, 1,007, 1,232, 1,540, 216, 1,591, and 1,434, respectively. these are not unique genes but rather represent overlapping annotations. There is extensive overlap (intersection) in gene annotation between different databases, and a gene can be annotated to multiple functional databases simultaneously (for example, a gene may have homologous sequences in both NR and Swiss_Prot databases), resulting in overlapping annotations.

Comment #16: The identification of "microRNA" in a bacterial genome should be carefully verified and explained, as microRNAs are primarily associated with eukaryotic systems.

Response #16: We thank the reviewer for pointing out this error, which was due to our imprecise wording. Our original intention was merely to indicate, in parentheses, the types of RNA that are generally encompassed by the term "other ncRNA," rather than specifically referring to snRNA, snoRNA, and microRNA. Therefore, to avoid any potential confusion, we have deleted the parenthetical annotations from lines 366 and 527.

Comment #17: A phylogenetic tree based on 16S rRNA or whole-genome comparisons (e.g., ANI or digital DNA–DNA hybridization) would strengthen species-level identification.

Response #17: Thank you very much for the suggestion from you and the other reviewer to construct a phylogenetic tree, and we have added a new phylogenetic tree (Figure S4) based on 16S rRNA gene sequences. Accordingly, we have added relevant text to lines 240–243 (Methods) and 327–336 (Results), with the changes highlighted in red.

Figure S4 Phylogenetic tree

Comment #18: The discussion needs revision. The statement that the strain was "sourced from alcoholic fermentation beverages" requires a supporting reference or clarification, as the subsequent sentence states that the species was first isolated from Japanese salt-free pickles.

Response #18: We thank the reviewer for raising this concern. We have marked in red on line 399 the statement that L. delbrueckii subsp. jakobsenii was isolated from alcoholic fermented beverages (reference 4). We trust that this addresses the reviewer's concern.

Comment #19: The authors should avoid using "we first isolated" unless this is supported by a comprehensive literature search demonstrating novelty.

Response #19: We thank the reviewer for the valuable comments. As suggested, we have deleted "first" in line 401 and revised the wording of the sentence accordingly.

Comment #20: If the strain was isolated from vaginal secretions, the manuscript should provide ethical approval information, informed consent details, and inclusion criteria for the donor population.

Response #20: We have revised and supplemented the "Study subjects" section of the manuscript and highlighted the changes in red in response to the reviewers' comments.

Comment #21: The relationship between the vaginal isolate and potential probiotic/functional significance should be discussed carefully, avoiding conclusions beyond the available evidence.

Response #21: We sincerely thank the reviewers for their constructive comments. We have carefully reviewed and revised the relevant parts of the manuscript. If any conclusions are not fully supported by the existing evidence, please point out the specific sentences, and we will make targeted revisions accordingly.

Comment #22: The authors should clarify whether the phenotypic characteristics listed in the first paragraph are derived from the original type strain description or from the current isolate.

Response #22: We were unsure which part of the phenotypic characterization in the first paragraph the reviewer was referring to. If the reviewer meant the phenotypic description of L. delbrueckii subsp. sunkii in the first part of the second paragraph of the Discussion section, that information was derived from reference 3, which describes the earliest isolated strain of L. delbrueckii subsp. sunkii from salt-free Japanese kimchi. We have already cited this reference in the manuscript to address the reviewer's concern.

Comment #23: The comparison between the pickle-derived strain and the vaginal isolate should include additional comparative data (e.g., growth conditions, biochemical profiles, genome-level differences) rather than only cell morphology.

Response #23: We sincerely thank the reviewer for the constructive comments. The cell morphology, growth conditions, and biochemical profiles of the strain isolated from salt-free pickled vegetables are based on Reference 3, as we detailed in lines 421–439 of the manuscript. However, since this reference only identifies this subspecies and does not include further genomic analyses, we are unable to compare the genomic differences between the salt-free pickle-derived strain and our vaginal isolate. We hope the reviewer will understand this limitation.

Comment #24: The term "D-lactate" should be supported by the analytical method used for lactate isomer determination.

Response #24: We thank the reviewer for raising this concern.The term 'D-lactate' in our manuscript was derived from reference 3, and we have now cited this reference accordingly in the text. We have marked this citation in red on line 417 of the manuscript.

Comment #25: If this section describes the newly isolated vaginal strain, provide complete phenotypic characterization rather than only morphological observations.

Response #25: In the revised manuscript, we have provided a comprehensive description of the phenotypic characteristics of L. delbrueckii subsp. sunkii isolated from vaginal secretions, including morphological features, growth characteristics, biochemical reactions, H₂O₂ production tests, acid production assays, antibacterial activity assays, and antimicrobial susceptibility tests. These are detailed in sections 421–439, 441–446, 450-454, and 467–470.

Comment #26: The statement that the strain "thrives in blood medium containing 5% NaCl" requires clarification because blood medium and NaCl tolerance represent different physiological tests.

Response #26: Because the medium contained 5% NaCl, we initially described it as "modified acidified blood agar plates" in line 128 of the original manuscript, which was imprecise. We have revised this sentence and marked the change in red. The detailed composition of the medium is as follows: 10 g peptone, 20 g glucose, 15 g agar powder, 5 g sodium chloride, 5 g beef extract powder, 5 g yeast extract powder, 5 g beef heart extract powder, 50 mL sterile 5% defibrinated sheep red blood cells, 50 mL fetal bovine serum, and 900 mL deionized distilled water, with citrate buffer (pH 4.0) added to adjust the final pH. NaCl tolerance can be observed through pure culture on modified acidified blood agar plate; good growth indicates that the strain has strong NaCl tolerance.

Comment #27: The authors should distinguish between experimentally measured phenotypes and genome-predicted functions to avoid overinterpretation.

Response #27: We thank the reviewer for the valuable comments. We have revised the experimental phenotype results in the Discussion section by integrating them with the genome annotation data to avoid mere data listing and overinterpretation. The revisions are highlighted in red.

Comment #28: Safety assessment should include additional analyses, such as virulence factor screening and antibiotic resistance gene evaluation, particularly for a strain isolated from human samples.

Response #28: We sincerely appreciate the reviewers' suggestions. We conducted additional virulence factor screening tests, using the published literature as a reference and applying the stringent reporting criteria of ≥80% amino acid identity, ≥70% VFDB reference sequence coverage, and E-value ≤1×10⁻⁵. No virulence factors meeting these criteria were detected in the VFDB Set A and Set B protein databases. Subsequently, we employed an extended screening standard of 40%–80% amino acid identity, requiring both query and reference sequence coverage ≥70% and E-value ≤1×10⁻⁵, which yielded 83 non-redundant VFDB homologous annotations. Among these, 42 were supported by both Set A and Set B, while 41 were supported solely by Set B. Based on the best hits of each protein in Set B, we classified the annotations according to VFDB standards. These annotations were primarily distributed across categories such as immune modulation, nutritional/metabolic factors, adherence, regulation, and stress survival. Relevant methods, results, and discussion are highlighted in red in lines 283-289, 376-389, and 474-485 of the article. We evaluated the antibiotic resistance genes, and in vitro susceptibility testing revealed sensitivity to 19 common antibiotics and resistance only to sulfonamides. Some genotype-phenotype discrepancies were observed; therefore, we recommend against antibiotic use during pregnancy to prevent potential impacts on fetal growth and development. The related content is marked in red in lines 463-474 of the article. The following image is the raw data with no results for VFDB annotation.

Thank you very much for your continued consideration. We look forward to hearing from you.

First author: Yi Wu

Thursday, August 27, 2026.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0363225.s014.docx (4.9MB, docx)

Decision Letter 1

António Machado

11 Oct 2026

Dear Dr. Wu,

Thank you for submitting your manuscript to PLOS One. After careful consideration, we feel that it has merit but does not fully meet PLOS One’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 25 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS One offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

António Machado

Academic Editor

PLOS One

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Dear authors,

I am pleased to inform you that one reviewer (Reviewer 2 already accepted the revised manuscript for publication and the other reviewer (Reviewer 1) requested some revisions for future publication endorsement. Please carefully answer Reviewer 1' concerns and rectify the manuscript following his/her comments.

Thank you for choosing PLOS ONE journal and best regards,

António Machado

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: The authors have substantially revised the manuscript and have adequately addressed most of the comments raised in the first round. In particular, the methodological description, phenotypic and genomic characterization, ethical information, phylogenetic identification, and evaluation of potential virulence factors have been considerably improved. However, I believe it is necessary to clarify or correct the following aspects:

1. Interpretation of antimicrobial susceptibility.

The Materials and Methods section states that the tests were performed according to CLSI M45, and in Table 1, the isolates are classified directly as “Sensitive” or “Resistant.” However, it must be clearly indicated which specific breakpoints or interpretive criteria were used for Lactobacillus delbrueckii and for each antimicrobial evaluated. The general reference to CLSI M45 does not clarify how these categories were established. If there are no validated clinical breakpoints for any of the microorganism–antimicrobial combinations studied, the results should be presented as inhibition diameters without classifying them as susceptible or resistant, or the alternative criterion used should be adequately justified.

2. Verification of experimental data.

In their response to comment 13, the authors indicate that during the review they detected that some of the GP/GN disc test results originally included corresponded to another strain, L. delbrueckii subsp. indicus. Since this involves experimental data pertaining to a different microorganism and is not a simple editorial error, I request that the authors confirm that they have re-examined the study’s primary data and verified that the tables, figures, and results currently presented correspond exclusively to the strain analyzed in this study.

3. Morphological description using SEM.

The response to the comment regarding the terms “cordyceps” and “silkworm” does not fully address the observation. If these terms do not correspond to established microbiological morphological descriptors, the inclusion of photographs of Cordyceps or the silkworm does not provide scientific justification for their use. We recommend removing these analogies and objectively describing the characteristics observed via SEM using appropriate morphological terminology.

4. Interpretation of the biological relevance of the isolate.

Although the conclusions have been tempered, there are still claims that go beyond the evidence obtained. For example, the abstract states that the results suggest this subspecies could play a role in human metabolism and in the vaginal microecological balance. The present study characterizes an isolate through in vitro assays and genomic analyses, but does not directly demonstrate these functions in vivo. This statement should be rephrased to clearly distinguish the results obtained from potential applications or hypotheses that must be tested in subsequent studies.

5. Distinction between the results of the present study and previously published data.

The authors have clarified in their responses that certain characteristics—including D-lactate and specific traits of the strain originally isolated from fermented vegetables—are derived from the prior literature. This distinction must be made entirely explicit in the manuscript so that the reader can clearly identify which characteristics were experimentally determined in the studied vaginal isolate and which correspond to previously described strains.

Finally, I recommend conducting one last careful review of the writing and editing. For example, the phrase “scanning electron microscopy scanning electron microscopy (SEM)” appears repeatedly in the abstract. These minor errors should be corrected.

Reviewer #2: Some minor inconsistencies were found in the Results section, particularly regarding the reported numerical values. The authors are advised to carefully verify all values against the corresponding tables and figures and revise the text accordingly. The language and grammar should also be improved throughout the manuscript to enhance clarity and readability.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes:  Sandra Pamela Cangui Panchi

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Nov 18;21(11):e0363225. doi: 10.1371/journal.pone.0363225.r004

Author response to Decision Letter 2


22 Oct 2026

António Machado, PhD

Academic Editor

plos one

Dear António Machado:

We would like to express our sincere gratitude for your and the reviewers’ valuable input on our manuscript (ID: PONE-D-26-06910), which we have revised in accordance with the reviewer’s remarks. We hereby resubmit a revised version of our manuscript for further consideration for publication in plos one.

We have responded to each of the reviewers’ comments in a point-by-point manner. In addition, we have provided a revised version of the manuscript with changes indicated in red font. We hope that the changes incorporated into the revised manuscript satisfactorily address the reviewers’ concerns.

In addition to revising the manuscript according to the reviewers' suggestions, we have carefully re-examined the entire text and corrected minor errors (including, but not limited to: punctuation, spacing, and other typographical issues), which have been highlighted in red.

6. Review Comments to the Author:

Reviewer #1: The authors have substantially revised the manuscript and have adequately addressed most of the comments raised in the first round. In particular, the methodological description, phenotypic and genomic characterization, ethical information, phylogenetic identification, and evaluation of potential virulence factors have been considerably improved. However, I believe it is necessary to clarify or correct the following aspects:

1. Interpretation of antimicrobial susceptibility.

The Materials and Methods section states that the tests were performed according to CLSI M45, and in Table 1, the isolates are classified directly as “Sensitive” or “Resistant.” However, it must be clearly indicated which specific breakpoints or interpretive criteria were used for Lactobacillus delbrueckii and for each antimicrobial evaluated. The general reference to CLSI M45 does not clarify how these categories were established. If there are no validated clinical breakpoints for any of the microorganism–antimicrobial combinations studied, the results should be presented as inhibition diameters without classifying them as susceptible or resistant, or the alternative criterion used should be adequately justified.

Response #1: We sincerely thank the reviewer for pointing out these issues and for the helpful suggestion. When we first studied this probiotic strain, we aimed to understand the effects of different antimicrobial agents on it. We reviewed the relevant literature and did not find a suitable antimicrobial susceptibility testing protocol for this strain. To address the reviewers' concern that "if there are no validated clinical breakpoints for any of the microbiome–antimicrobial combinations studied, the results should be presented as inhibition diameters without classifying them as susceptible or resistant," we conducted additional breakpoint determination experiments to verify the results of the previous disk diffusion method. All antimicrobial susceptibility testing was performed in strict accordance with CLSI M45 (3rd ed.), Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. Based on the antibiotic selection for Lactobacillus and the susceptibility test results on pp. 38–39 of CLSI M45, interpretive breakpoints were selected/adopted (Supplementary Table 1). If no breakpoint was available, the isolate was not classified as "susceptible" or "resistant," as suggested by the reviewer, and the result was recorded as "-" (not determined). After confirmation by both broth microdilution and disk diffusion, only the sulfonamide agents showed resistance by both methods and were ultimately classified as resistant. We have also revised the Methods, Results, and Discussion sections accordingly; the changes are marked in red. In lines 38, 327 and 473, we have revised the statement that the strain is susceptible to 19 common antibiotics, changing "19" to "7." At the same time, we corrected the inhibition zone diameter for the SXT 25 disk in the disk diffusion method from 0 mm to 6 mm. Although no inhibition zone was observed, we overlooked that the disk itself is 6 mm in diameter; therefore, the value should be recorded as 6 mm rather than 0 mm. Although bacterial growth was observed in both CIP and LEV wells with the broth dilution method, inhibition zones were observed with the disk diffusion method. Because no standard interpretive criteria are available, we could not determine whether these two drugs are susceptible or resistant. The abbreviations TCY, LVX, and MEM used for drug names in the disk diffusion method in Table 1 are inconsistent with TET, LEV, and MRP used in the broth dilution method in Supplementary Table 2. We have standardized these abbreviations in Table 1 to avoid potential concerns from the reviewers. We additionally tested two reagent plates, DL-96STAPH and DL-96STREP; however, the DL-96STAPH plate was invalid. No bacterial growth was observed in any well of the broth microdilution susceptibility test, including the positive control well.

Supplementary Table 1. Antimicrobial agent selection and interpretive breakpoints for antimicrobial susceptibility testing of the genus Lactobacillus

Antimicrobial agents MIC value of dilution method

S I R

Penicillin ≤ 8 - -

Ampicillin ≤ 8 - -

Imipenem ≤ 0.5 1 ≥ 2

Meropenem ≤ 1 2 ≥ 4

Vancomycin ≤ 2 4 ~ 8 ≥ 16

Erythromycin ≤ 0.5 1 ~ 4 ≥ 8

Clindamycin ≤ 0.5 1 ≥ 2

Linezolid ≤ 4 - -

Supplementary Figure 1. Original drug sensitivity test results using dilution methodC+ indicates the positive control well. Bacterial growth is observed in SXT, CIP, and LEV wells.

Supplementary Table 2. Results of drug sensitivity test using micro broth dilution method

Type of drug dilution method MIC value(µg/ml) Results

abbreviation Full name

Penicillins AMP Ampicillin ≤0.25 s

Penicillins PEN Penicillin ≤0.06 s

Sulfonamides SXT Trimethoprim/Sulfamethoxazole ≥4/76 -

Lincosamides CLI Clindamycin ≤0.25 s

Macrolides ERY Erythromycin ≤0.25 s

Cephalosporins (2nd generation) CXM Cefuroxime ≤0.5 -

Cephalosporins (3rd generation) CRO Ceftriaxone ≤0.5 -

Rifamycins RIF Rifampicin ≤0.5 -

β-lactam AMC Amoxicillin/Clavulanate ≤1.0/0.5 -

Glycopeptides VAN Vancomycin ≤1 s

Glycopeptides TEC Teicoplanin ≤1 -

Quinolones CIP Ciprofloxacin ≥2 -

Quinolones LEV Levofloxacin 8 -

Oxazolidinones LNZ Linezolid ≤2 s

Tetracyclines TET Tetracycline ≤1 -

Aminoglycosides HLG High-level gentamicin ≤500 -

Aminoglycosides HLS High-level streptomycin ≤1000 -

Tetracyclines MI Minocycline ≤4 -

Carbapenems MRP Meropenem ≤0.25 s

Nitrofuran antibiotics FD Nitrofurantoin ≤16 -

Lincosamides Er Inducible clindamycin resistance ≤1.0/0.5 -

Note: "-" indicates that the result cannot be determined.

Supplementary Figure 2. Image of SXT disk diffusion test showing resistance

Table 1. Antimicrobial susceptibility of Lactobacillus delbrueckii subsp. sunkii against 20 antibiotics (mean ± SD).

Type of drug Kirby–Bauer streaking method Zone of inhibition (diameter, mm) Dilution method MIC value(µg/ml) Results

ID/content (μg) Name ID Name

Oxazolidinones LNZ 30 Linezolid 40 ± 2 LNZ Linezolid ≤2 Sensitive

Quinolones CIP 5 Ciprofloxacin 18 ± 2 CIP Ciprofloxacin ≥2 -

Quinolones LVX 5 Levofloxacin 20 ± 2 LVX Levofloxacin 8 -

Quinolones GAT 5 Gatifloxacin 26 ± 2 - - - -

Tetracyclines TCY 30 Tetracycline 28 ± 2 TCY Tetracycline ≤1 -

Rifamycins RIF 5 Rifampicin 25 ± 2 RIF Rifampicin ≤0.5 -

Chloramphenicols CHL 30 Chloramphenicol 36 ± 2 - - - -

Penicillins AMP 10 Ampicillin 40 ± 1 AMP Ampicillin ≤0.25 Sensitive

Penicillins PEN 10 Penicillin 47 ± 2 PEN Penicillin ≤0.06 Sensitive

Glycopeptides VAN 30 Vancomycin 30 ± 1 VAN Vancomycin ≤1 Sensitive

Aminoglycosides GEN 10 Gentamicin 21 ± 2 GEN High-level gentamicin ≤500 -

Aminoglycosides AMK 30 Amikacin 22 ± 1 - - - -

Lincosamides CLI 2 Clindamycin 26 ± 1 CLI Clindamycin ≤0.25 Sensitive

Cephalosporins (3rd generation) CRO 30 Ceftriaxone 36 ± 1 CRO Ceftriaxone ≤0.5 -

Cephalosporins (4th generation) FEP 30 Cefepime 40 ± 1 - - - -

Cephalosporins (3rd generation) CTX 30 Cefotaxime 41 ± 2 - - - -

Macrolides ERY 15 Erythromycin 41 ± 2 ERY Erythromycin ≤0.25 Sensitive

Sulfonamides SXT 25 Trimethoprim/

Sulfamethoxazole 6 ± 0 SXT Trimethoprim/Sulfamethoxazole ≥4/76 Resistant

Carbapenems IPM 10 Imipenem 49 ± 2 - - - -

Carbapenems MEM 10 Meropenem 40 ± 1 MEM Meropenem ≤0.25 Sensitive

Note: “-” indicates that no result is available or the result cannot be determined.

2. Verification of experimental data.

In their response to comment 13, the authors indicate that during the review they detected that some of the GP/GN disc test results originally included corresponded to another strain, L. delbrueckii subsp. indicus. Since this involves experimental data pertaining to a different microorganism and is not a simple editorial error, I request that the authors confirm that they have re-examined the study’s primary data and verified that the tables, figures, and results currently presented correspond exclusively to the strain analyzed in this study.

Response #2: We sincerely thank the reviewers for their valuable comments. We have carefully re-checked and verified all the tables, figures, and data in the article. The following two tables show the results of the GP/GN biochemical identification cards:

Table 1 Results of biochemical reaction for gram-positive identification cards for Lactobacillus delbrueckii subsp. sunkii

Table 2 Results of biochemical reaction for gram-negative identification cards for Lactobacillus delbrueckii subsp. sunkii

3. Morphological description using SEM.

The response to the comment regarding the terms “cordyceps” and “silkworm” does not fully address the observation. If these terms do not correspond to established microbiological morphological descriptors, the inclusion of photographs of Cordyceps or the silkworm does not provide scientific justification for their use. We recommend removing these analogies and objectively describing the characteristics observed via SEM using appropriate morphological terminology.

Response #3: Thank you very much for the reviewer's comments. We have removed the terms "cordyceps" and "silkworm" and provided a new morphological description. We have changed the original description in line 300 from "SEM revealed bacterial cells measuring 1–10 μm in length, exhibiting cordyceps-like or silkworm-shaped structures." to "SEM revealed bacterial cells of varying lengths and sizes, approximately 1–10 μm long." and marked it in red.

4. Interpretation of the biological relevance of the isolate.

Although the conclusions have been tempered, there are still claims that go beyond the evidence obtained. For example, the abstract states that the results suggest this subspecies could play a role in human metabolism and in the vaginal microecological balance. The present study characterizes an isolate through in vitro assays and genomic analyses, but does not directly demonstrate these functions in vivo. This statement should be rephrased to clearly distinguish the results obtained from potential applications or hypotheses that must be tested in subsequent studies.

Response #4: Thank you very much for the reviewer's comments. We have revised the wording and changed the conclusions in line 52 from "These findings suggest that this species may play a role in human metabolism and vaginal microbiota balance." to "These findings suggest that this species may be associated with human metabolism and vaginal microbiota balance," We have also changed the conclusions in lines 565–566 from "We suggest that this strain may play an essential role in vaginal self-cleaning and in maintaining the balance of the vaginal microbiota. " to "We suggest that this strain may be associated with human metabolism and vaginal microbiota balance," and marked the change in red.

5. Distinction between the results of the present study and previously published data.

The authors have clarified in their responses that certain characteristics—including D-lactate and specific traits of the strain originally isolated from fermented vegetables—are derived from the prior literature. This distinction must be made entirely explicit in the manuscript so that the reader can clearly identify which characteristics were experimentally determined in the studied vaginal isolate and which correspond to previously described strains.

Finally, I recommend conducting one last careful review of the writing and editing. For example, the phrase “scanning electron microscopy scanning electron microscopy (SEM)” appears repeatedly in the abstract. These minor errors should be corrected.

Response #5: Thank you very much for the reviewer's suggestions. The description of the strain in lines 413–425 of the Discussion is taken from the cited reference 3, while lines 425–444 present our experimental results on the vaginal isolates. We have revised lines 415–416 and 426 to better distinguish between cited data and our experimental data. In addition, the repeated term "scanning electron microscopy scanning electron microscopy (SEM)" in line 32 of the Abstract has been revised, and the entire manuscript has been thoroughly reviewed. All modifications are marked in red. Once again, we thank the reviewers for their diligent efforts on this manuscript.

Reviewer #2: Some minor inconsistencies were found in the Results section, particularly regarding the reported numerical values. The authors are advised to carefully verify all values against the corresponding tables and figures and revise the text accordingly. The language and grammar should also be improved throughout the manuscript to enhance clarity and readability.

Response: We sincerely appreciate the reviewers’ comments. We have carefully checked the data in the main text and the corresponding figures and tables to ensure consistency, and have made improvements to the grammar throughout the manuscript. The revisions have been marked in red. Once again, we thank the reviewers for their diligent efforts on this manuscript.

Thank you very much for your continued consideration. We look forward to hearing from you.

First author: Yi Wu

Wednesday, October 21, 2026.

Attachment

Submitted filename: Response_to_Reviewers_auresp_2.docx

pone.0363225.s015.docx (741.2KB, docx)

Decision Letter 2

António Machado

5 Nov 2026

Analysis of the biological characteristics and gene function of Lactobacillus delbrueckii subsp. sunkii

PONE-D-26-06910R2

Dear authors,

I am pleased to inform you that both reviewers enjoyed the manuscript very much and endorsed the revised manuscript for publication.

Thank you for choosing Plos ONE journal to publish your study.

Best regards,

António Machado

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

**********

Reviewer #1: (No Response)

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes:  Sandra Pamela Cangui Panchi

**********

Acceptance letter

António Machado

PONE-D-26-06910R2

PLOS One

Dear Dr. Wu,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS One and supporting open access.

Kind regards,

PLOS One Editorial Office Staff

on behalf of

Dr. António Machado

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Colony characteristics of Lactobacillus delbrueckii subsp. sunkii on modified blood agar.

    (TIF)

    pone.0363225.s001.tif (2.6MB, tif)
    S2 Fig. Inhibition of Escherichia coli growth by Lactobacillus delbrueckii subsp. sunkii.

    Note: A. Experimental group (E. coli colony diameter: 6 mm); B. Control group (E. coli colony diameter: 20 mm).

    (TIF)

    pone.0363225.s002.tif (370.1KB, tif)
    S3 Fig. Inhibition of Staphylococcus aureus growth by Lactobacillus delbrueckii subsp. sunkii.

    Note: A. Experimental group (S. aureus colony diameter: 4 mm); B. Control group (S. aureus colony diameter: 12 mm).

    (TIF)

    pone.0363225.s003.tif (447.7KB, tif)
    S4 Fig. Phylogenetic tree.

    Note: The branch length represents the evolutionary distance, with more closely related species positioned closer together on the phylogenetic tree. The branch length also reflects the degree of sequence differentiation among strains, with larger values indicating greater differentiation.

    (TIFF)

    pone.0363225.s004.tiff (9.3MB, tiff)
    S5 Fig. COG functional classification of genes.

    Note: X-axis: COG functional categories; Y-axis: number of annotated genes per category. Explanations for each category are provided on the right.

    (TIF)

    pone.0363225.s005.tif (232.3KB, tif)
    S6 Fig. Distribution of CAZy families.

    Note: X-axis: CAZy family classifications; Y-axis: gene counts.

    (TIF)

    pone.0363225.s006.tif (4.3MB, tif)
    S7 Fig. KEGG pathway enrichment.

    Note: Y-axis: secondary classifications of biological pathways; X-axis: gene counts. Colors represent primary pathway categories.

    (TIF)

    pone.0363225.s007.tif (4.2MB, tif)
    S8 Fig. GO term distribution of target genes.

    Note: Y-axis: GO terms; X-axis: gene counts. Colors distinguish Biological Process (BP), Cellular Component (CC), and Molecular Function (MF).

    (TIF)

    pone.0363225.s008.tif (2.7MB, tif)
    S9 Fig. NR species distribution.

    Note: Pie chart showing species proportions, with colors representing distinct taxa.

    (TIF)

    pone.0363225.s009.tif (13.7MB, tif)
    S10 Fig. Genome atlas (Circos plot).

    Note: Concentric circles display the following, from outermost to innermost: outermost circle: genomic coordinates; second circle: GC content; third circle: coding genes on the positive strand (red); fourth circle: coding genes on the negative strand (green); fifth circle: non-coding RNAs (ncRNAs) on the positive strand (blue); sixth circle: ncRNAs on the negative strand (purple); innermost circle: long repetitive sequences (orange).

    (TIF)

    pone.0363225.s010.tif (5.7MB, tif)
    S1 Table. Primers for the 16S rRNA gene with P5 and P7 adapters.

    (DOCX)

    pone.0363225.s011.docx (12.4KB, docx)
    S2 Table. Summary statistics of the analytical results.

    (DOCX)

    pone.0363225.s012.docx (12.9KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0363225.s014.docx (4.9MB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_2.docx

    pone.0363225.s015.docx (741.2KB, docx)

    Data Availability Statement

    The genome sequence was deposited in the NCBI database under accession number PRJNA893246 (https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA893246). The strain is preserved at CCTCC (No. CCTCC M 20221248). Supplementary figures and tables are provided in the online version.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES